<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art><ui>cc10020</ui><ji>CCJ</ji><fm>
<dochead>Review</dochead>
<bibl>
<title>
<p>Clinical review: Ketones and brain injury</p>
</title>
<aug>
<au id="A1"><snm>White</snm><fnm>Hayden</fnm><insr iid="I1"/><email>hayden_white@health.qld.gov.au</email></au>
<au ca="yes" id="A2"><snm>Venkatesh</snm><fnm>Balasubramanian</fnm><insr iid="I2"/><email>bala_venkatesh@health.qld.gov.au</email></au>
</aug>
<insg>
<ins id="I1"><p>Department of Intensive Care, Griffiths University, Logan Hospital, Meadowbrook, Queensland 4131, Australia</p></ins>
<ins id="I2"><p>Department of Critical Care Medicine, University of Queensland, Princess Alexandra &amp; Wesley Hospitals, Brisbane, Queensland 4102, Australia</p></ins>
</insg>
<source>Critical Care</source>
<issn>1364-8535</issn>
<pubdate>2011</pubdate>
<volume>15</volume>
<issue>2</issue>
<fpage>219</fpage>
<url>http://ccforum.com/content/15/2/219</url>
<xrefbib><pubidlist><pubid idtype="pmpid">21489321</pubid><pubid idtype="doi">10.1186/cc10020</pubid></pubidlist></xrefbib>
</bibl>
<history><pub><date><day>6</day><month>4</month><year>2011</year></date></pub></history>
<cpyrt><year>2011</year><collab>BioMed Central Ltd</collab></cpyrt>
<abs>
<sec>
<st>
<p>Abstract</p>
</st>
<p>Although much feared by clinicians, the ability to produce ketones has allowed humans to withstand prolonged periods of starvation. At such times, ketones can supply up to 50% of basal energy requirements. More interesting, however, is the fact that ketones can provide as much as 70% of the brain's energy needs, more efficiently than glucose. Studies suggest that during times of acute brain injury, cerebral uptake of ketones increases significantly. Researchers have thus attempted to attenuate the effects of cerebral injury by administering ketones exogenously. Hypertonic saline is commonly utilized for management of intracranial hypertension following cerebral injury. A solution containing both hypertonic saline and ketones may prove ideal for managing the dual problems of refractory intracranial hypertension and low cerebral energy levels. The purpose of the present review is to explore the physiology of ketone body utilization by the brain in health and in a variety of neurological conditions, and to discuss the potential for ketone supplementation as a therapeutic option in traumatic brain injury.</p>
</sec>
</abs>
</fm><meta>
<classifications>
<classification subtype="pubmedcentral-release-delay-information" type="BMC">
<?release-delay 12|0 ?>
</classification>
</classifications>
</meta><bdy>
<sec>
<st>
<p>Introduction</p>
</st>
<p>Ketogenesis is the process by which ketone bodies (KB), during times of starvation, are produced via fatty acid metabolism. Although much feared by physicians, mild ketosis can have therapeutic potential in a variety of disparate disease states. The principle ketones include acetoacetate (AcAc), &#946;-hydroxybutyrate (BHB) and ace-tone. In times of starvation and low insulin levels, ketones supply up to 50% of basal energy requirements for most tissues, and up to 70% for the brain. Although glucose is the main metabolic substrate for neurons, ketones are capable of fulfilling the energy requirements of the brain.</p>
<p>The purpose of the present review is to explore the physiology of ketone body utilization by the brain in health and a variety of neurological conditions, and to discuss the potential for ketone supplementation as a therapeutic option in traumatic brain injury (TBI).</p>
</sec>
<sec>
<st>
<p>Ketones, metabolism and the brain</p>
</st>
<sec>
<st>
<p>Ketone metabolism</p>
</st>
<p>Ketones are by-products of fat metabolism and are produced in hepatic mitochondria <abbrgrp>
<abbr bid="B1">1</abbr>
</abbrgrp>. More specifically, the three KB are: AcAc - if not oxidized to form usable energy, this is the source of the two other KB; acetone - not an energy source, but instead exhaled or excreted as waste; and BHB - not technically a ketone, but reversibly produced from AcAc.</p>
<p>The precursor for the synthesis of ketones is acetyl coenzyme A (acetyl CoA), which is formed by &#946;-oxidation of free fatty acids in the liver. The two important determinants of ketogenesis are the availability of acetyl CoA and the mobilization of fatty acids liberated from white adipose tissue during fasting or catecholaminergic stress <abbrgrp>
<abbr bid="B2">2</abbr>
<abbr bid="B3">3</abbr>
</abbrgrp>.</p>
<p>AcAc is the central ketone body. AcAc is reduced to BHB by &#946;-hydroxybutyrate dehydrogenase (BHD) in a NADH-requiring reversible reaction <abbrgrp>
<abbr bid="B3">3</abbr>
</abbrgrp>:</p>
<p>
<display-formula>
<graphic file="cc10020-i1.gif"/>
</display-formula>
</p>
<p>The extent of this reaction depends on the state of the cellular pool of NAD+ <abbrgrp>
<abbr bid="B4">4</abbr>
</abbrgrp>. When highly reduced, most or all ketones will be in the form of BHB. The ratio of BHB to AcAc reflects the redox state within the mitochondrial matrix <abbrgrp>
<abbr bid="B5">5</abbr>
</abbrgrp>. BHB is nonvolatile and is chemically stable. This ketone body's only metabolic fate is interconversion with AcAc. Once synthesized, ketones diffuse into the circulation.</p>
</sec>
<sec>
<st>
<p>Fate of circulating ketones</p>
</st>
<p>Plasma concentrations of circulating KB range from &lt;0.1 mM/l in the postprandial state to as much as 6 mM/l during fasting, with levels reaching 25 mM/l in diabetic ketoacidosis <abbrgrp>
<abbr bid="B6">6</abbr>
<abbr bid="B7">7</abbr>
<abbr bid="B8">8</abbr>
</abbrgrp>. Under normal dietary conditions, ketogenesis from fatty acids is at very low levels. This is attributable to the relatively high blood levels of the ketogenesis-inhibiting hormone insulin, and low blood levels of ketogenesis-promoting hormones, glucagon and cortisol <abbrgrp>
<abbr bid="B2">2</abbr>
</abbrgrp>. One of the prerequisites for ketogenesis is therefore low levels of circulating insulin, as seen during starvation and diabetic ketoacidosis</p>
<p>The fate of circulating KB is to be taken up by extra-hepatic tissues, although 10 to 20% may be lost in the urine <abbrgrp>
<abbr bid="B8">8</abbr>
<abbr bid="B9">9</abbr>
</abbrgrp>. KB provide an energy source for several tissues including the brain, skeletal muscle, myocardium and liver, although the heart and kidney have the greatest capacity for utilization <abbrgrp>
<abbr bid="B10">10</abbr>
</abbrgrp>. The rate of utilization appears to be a function of the circulating plasma levels <abbrgrp>
<abbr bid="B11">11</abbr>
<abbr bid="B12">12</abbr>
<abbr bid="B13">13</abbr>
</abbrgrp>.</p>
</sec>
<sec>
<st>
<p>Ketones and critical illness</p>
</st>
<p>The major illness associated by intensive care physicians with ketosis is diabetic ketoacidosis. Outside diabetic ketoacidosis, ketone measurement is not routinely performed and has been largely used as a research tool to quantify cellular redox status. The arterial ketone body ratio (AKBR) is utilized to reflect the mitochondrial redox status of hepatic cells and may reflect cellular energy status in a number of conditions including hemorrhage, hypoxia, sepsis and hepatic resection <abbrgrp>
<abbr bid="B14">14</abbr>
</abbrgrp>. The AKBR (ratio of AcAc to BHB) reflects the cellular NAD<sup>+</sup>/NADH ratio, which cannot be measured directly and is linked to the phosphorylation potential of the cell (see equation above). In critically ill patients, the entry of acetyl CoA into the tricarboxylic acid cycle is limited. Acetyl CoA consequently combines with another molecule of acetyl CoA to form acetoacetic acid, which in turn is converted to BHB leading to an altered NAD<sup>+</sup>/NADH ratio and a decreased AKBR <abbrgrp>
<abbr bid="B14">14</abbr>
<abbr bid="B15">15</abbr>
</abbrgrp>. A reduced AKBR is therefore a sign of an inefficient tricarboxylic acid cycle. The AKBR has also been used as an indirect marker of the hepatocellular functional status as the predominant site of metabolism of the ketones is in the liver.</p>
<p>Not surprisingly, metabolic failure at the cellular level is associated with worse clinical outcomes. A low AKBR is associated with poor outcomes in both animal and human models of illness. Yassen and colleagues measured the AKBR in 20 critically ill patients <abbrgrp>
<abbr bid="B15">15</abbr>
</abbrgrp>. They demonstrated a progressive decrease in those patients with septic shock who died. In a study of critically ill heart failure patients, Limuro and colleagues noted a survival of only 15% of patients with AKBR &lt;0.7 <abbrgrp>
<abbr bid="B16">16</abbr>
</abbrgrp>. Dresing and colleagues found the AKBR to be significantly lower in nonsurvivors than survivors in 30 polytrauma patients (0.6 vs. 1.3; <it>P </it>= 0.001) <abbrgrp>
<abbr bid="B17">17</abbr>
</abbrgrp>. Levy and colleagues, however, failed to find a difference in AKBR levels between survivors and nonsurvivors in their cohort of septic patients <abbrgrp>
<abbr bid="B18">18</abbr>
</abbrgrp>. In conjunction with the lactate:pyruvate ratio, the AKBR may provide further insight into the cellular redox potential of critically ill patients.</p>
</sec>
<sec>
<st>
<p>Ketones and the brain</p>
</st>
<p>Glucose is the major fuel for the brain in humans on a balanced diet. More recently it was proposed that other substances such as lactate and pyruvate may be utilized by neurons to sustain their activity <abbrgrp>
<abbr bid="B19">19</abbr>
</abbrgrp>. Furthermore, during times of starvation, the brain has the capacity to adapt to the use of ketones as its major energy source (and in the metabolic disease diabetes mellitus). In longstanding starvation, ketones can provide 60 to 70% of the energy needs of the brain <abbrgrp>
<abbr bid="B20">20</abbr>
</abbrgrp>. The 1.5 kg human brain utilizes 100 to 150 g glucose per day and 20% of the total body oxygen consumption at rest <abbrgrp>
<abbr bid="B7">7</abbr>
</abbrgrp>. Protein catabolism can supply somewhere between 17 and 32 g glucose per day, well below the minimum daily cerebral glucose requirements <abbrgrp>
<abbr bid="B21">21</abbr>
</abbrgrp>. In fact, to supply sufficient glucose to support brain metabolic requirements from protein alone would lead to death in about 10 days instead of the 57 to 73 days <abbrgrp>
<abbr bid="B22">22</abbr>
</abbrgrp>. Moreover in subjects undergoing total starvation for 30 days, the decrease in hunger coincides with the elevation of blood ketones to 7 mM/l. During periods of ongoing starvation, an average-size person produces about 150 g KB per day <abbrgrp>
<abbr bid="B23">23</abbr>
</abbrgrp>. One should note, however, that ketones are incapable of maintaining or restoring normal cerebral function in the complete absence of glucose.</p>
<p>Astrocytes may play a significant role in the regulation of brain energy metabolism <abbrgrp>
<abbr bid="B24">24</abbr>
</abbrgrp>. Reports suggest that astrocytes can produce KB from fatty acids and leucine and are involved with other pathways of lipid metabolism, such as lipid synthesis and lipoprotein secretion <abbrgrp>
<abbr bid="B25">25</abbr>
<abbr bid="B26">26</abbr>
<abbr bid="B27">27</abbr>
<abbr bid="B28">28</abbr>
</abbrgrp>. Furthermore, it appears that the production of lactate and KB by astrocytes may increase secondary to neurotransmitters released during enhance synaptic activity <abbrgrp>
<abbr bid="B29">29</abbr>
<abbr bid="B30">30</abbr>
</abbrgrp>.</p>
<p>Although the implications of ketone body production by astrocytes are still unclear, the fact that astrocytes outnumber neurons approximately 9:1 and occupy at least 50% of the cerebral volume suggests this constitutes a quantitatively important pathway in the brain <abbrgrp>
<abbr bid="B31">31</abbr>
</abbrgrp>.</p>
</sec>
<sec>
<st>
<p>Regulation of cerebral ketone uptake</p>
</st>
<p>As previously noted, humans can achieve very high circulating KB concentrations during prolonged fasting, up to 9 mM/l (range 5.8 to 9.7 mM/l) <abbrgrp>
<abbr bid="B20">20</abbr>
</abbrgrp>. The plasma concentration of KB is a significant factor affecting the rate of cerebral uptake. The blood-brain barrier (BBB) is relatively impermeable to most hydrophilic substances, such as KB, unless they are transported by a carrier protein. A family of proteins involved in the transport of monocarboxylic acids such as lactic acid and pyruvate across cellular membranes, called monocarboxylic acid transporters (MCT1 and MCT2), are thought to play an integral role.</p>
<p>It is not yet understood how MCTs are regulated. KB are transported at different rates, with the uptake of AcAc being twice that of BHB at a given arterial concentration <abbrgrp>
<abbr bid="B12">12</abbr>
</abbrgrp>. Furthermore, prolonged fasting appears to increase the BBB uptake of ketones, with some researchers demonstrating an eightfold increase in the expression of MCT1 <abbrgrp>
<abbr bid="B32">32</abbr>
</abbrgrp>. Similarly, Hasselbalch and colleagues reported a 13-fold increase in cerebral uptake of BHB in humans following several days of fasting <abbrgrp>
<abbr bid="B33">33</abbr>
</abbrgrp>. In contrast, rapidly increasing plasma ketone concentrations do not lead to such a significant increase in cerebral ketone uptake. Pan and colleagues noted a much smaller increase in cerebral ketone concentrations following a rapid intravenous infusion of BHB as compared with prolonged fasting, implying that MCT upregulation is partly dependent on the length of exposure to increased plasma ketone levels <abbrgrp>
<abbr bid="B34">34</abbr>
<abbr bid="B35">35</abbr>
</abbrgrp>.</p>
<p>Once across the BBB, KB enter brain cells to support cellular energy requirements. Studies of the uptake of KB by brain cells suggest entry occurs by two mechanisms: diffusion and a carrier-mediated process. MCTs have been demonstrated on neurons and glial cells although their role here appears less significant as compared with that on the BBB. The impact of mitochondrial enzyme activity involved in ketone metabolism is less clear. Certainly, mitochondrial enzymes can be upregulated by increased levels of BHB, as has been demonstrated following exposure to ketones through starvation or a prolonged high-fat diet <abbrgrp>
<abbr bid="B12">12</abbr>
<abbr bid="B36">36</abbr>
<abbr bid="B37">37</abbr>
<abbr bid="B38">38</abbr>
<abbr bid="B39">39</abbr>
</abbrgrp>. In summary, there- fore, a prolonged high blood ketone concentration leads to an increased rate of cerebral ketone uptake and metabolism.</p>
</sec>
<sec>
<st>
<p>Regional variation in ketone body metabolism</p>
</st>
<p>Data for the regional variation in ketone body metabolism are based largely on animal studies. Hawkins and colleagues and Morris noted that KB uptake varies from one brain region to another <abbrgrp>
<abbr bid="B40">40</abbr>
<abbr bid="B41">41</abbr>
</abbrgrp>. Following an intravenous administration of radioactive BHB to adult rats, uptake was greatest in the cerebral cortex (deep layers), in the superior and inferior colliculi, and in regions where the BBB is absent <abbrgrp>
<abbr bid="B40">40</abbr>
<abbr bid="B41">41</abbr>
</abbrgrp>. Areas with a low metabolic rate such as the corpus callosum and other white-matter structures demonstrated greatly reduced uptake. Interestingly, the pattern of KB uptake resembled that of glucose, except in the superficial layers of the cortex where glucose uptake was higher <abbrgrp>
<abbr bid="B42">42</abbr>
</abbrgrp>. Similarly, MCT1 expression in the brain may resemble the pattern of KB uptake with some exceptions as MCT1 is found on glia and neurons as well as on BBB epithelial cells and because the pituitary and pineal have no BBB.</p>
</sec>
<sec>
<st>
<p>Neuroprotective effects of ketones</p>
</st>
<p>Neuroprotection is the mechanisms and strategies that, once implemented, may lead to salvage, recovery or regeneration of the nervous system. Ketones may have a neuroprotective effect (see Figure <figr fid="F1">1</figr>). Ketones represent an alternative fuel for both the normal and the injured brain <abbrgrp>
<abbr bid="B43">43</abbr>
</abbrgrp>.</p>
<fig id="F1"><title><p>Figure 1</p></title><caption><p>Potential neuroprotective mechanisms of ketones</p></caption><text>
   <p><b>Potential neuroprotective mechanisms of ketones</b>. Ketones (1) require only three enzymatic steps to enter the tricarboxylic acid (TCA) cycle, (2) reduce the NAD couple, (3) decrease free radical formation, (4) increase production of ATP, (5) increase mitochondrial uncoupling, (6) increase glutathione peroxidase activity, and (7) inhibit pyruvate entry into the TCA cycle. CoA, coenzyme A; GSH, reduced glutathione; GSSG, oxidized glutathione; NAD<sup>+</sup>, nicotinamide adenine dinucleotide; NADH, nicotinamide adenine dinucleotide hydrogenase; NADP, nicotinamide adenine dinucleotide phosphate; NADPH, nicotinamide adenine dinucleotide phosphate hydrogenase; OHB, hydroxybutyrate; PPP, pentose phosphate pathway; UCP, uncoupling protein. Reprinted with permission from <abbrgrp><abbr bid="B43">43</abbr></abbrgrp>.</p>
</text><graphic file="cc10020-1"/></fig>
<p>Firstly, BHB is more energy efficient than glucose and can stimulate mitochondrial biogenesis via the upregulation of genes encoding energy metabolism and mitochondrial enzymes <abbrgrp>
<abbr bid="B44">44</abbr>
</abbrgrp>. There is a marked increase in the free energy of ATP hydrolysis, as demonstrated by a 25% increase in hydrolytic work of isolated rat perfused heart preparations when exposed to KB <abbrgrp>
<abbr bid="B45">45</abbr>
</abbrgrp>. Also, ketones increase the intermediary metabolites delivered to the citric acid cycle with a 16-fold elevation in acetyl CoA content.</p>
<p>Secondly, ketones protect against glutamate-mediated apoptosis and necrosis through the attenuation of the formation of reactive oxidant species. Ketones can oxidize coenzyme Q, thus decreasing mitochondrial free radical formation. Additionally, the reduction of NAD favors reduction of glutathione, which ultimately favors destruction of hydrogen peroxide by glutathione peroxidase reaction <abbrgrp>
<abbr bid="B46">46</abbr>
<abbr bid="B47">47</abbr>
</abbrgrp>.</p>
<p>Thirdly, ketones enhance the conversion of glutamate to GABA with the subsequence enhancement of GABA- mediated inhibition <abbrgrp>
<abbr bid="B48">48</abbr>
<abbr bid="B49">49</abbr>
</abbrgrp>. Cerebral ketone uptake also increases cerebral blood flow <abbrgrp>
<abbr bid="B50">50</abbr>
</abbrgrp>.</p>
<p>Fourthly, cell death from apoptosis is attenuated by ketone ingestion <abbrgrp>
<abbr bid="B48">48</abbr>
</abbrgrp>. Mechanisms include reductions in activation of caspase-3, increases in calbindin and prevention of accumulation of the protein clusterin.</p>
<p>Lastly, cerebral ketone metabolism alters cerebral blood flow <abbrgrp>
<abbr bid="B50">50</abbr>
</abbrgrp>. Hasselbalch and colleagues demonstrated a 39% increase in cerebral blood flow following an infusion of sodium BHB.</p>
</sec>
</sec>
<sec>
<st>
<p>Current state of research - changes in ketone metabolism during brain injury</p>
</st>
<sec>
<st>
<p>Models of injury - animal studies</p>
</st>
<p>Adaptive changes to cerebral ketone metabolism during development and starvation are well documented. How-ever, there is evidence that other conditions including TBI, ischemia, hemorrhagic shock and hypoxia induce rapid changes in both vascular and cellular transporters that favor ketone uptake and metabolism. In addition, ketone-metabolizing enzymes demonstrate the ability to change in response to neuropathologic conditions. Collectively, these adaptations suggest that the brain may be more receptive to ketone metabolism under neuropathic conditions.</p>
<p>Researchers have demonstrated an increase in MCT1 and MCT2 expression following cerebral injury <abbrgrp>
<abbr bid="B51">51</abbr>
</abbrgrp>. Similarly, ketone-metabolizing enzyme expression also appears to alter. Utilization of BHB in the brain is contingent on its conversion to AcAc by BHD, which is scarce in the adult brain, especially in the basal ganglia. Studies confirm a significant increase in BHD activity following cerebral insult <abbrgrp>
<abbr bid="B52">52</abbr>
</abbrgrp>.</p>
<p>The brain's ability to utilize exogenous KB is altered. At times of oxidative stress, the ability of the brain to use glucose as a substrate for metabolic activity may become compromised. Certainly, hyperglycemia has been repeatedly shown to be deleterious to the injured brain <abbrgrp>
<abbr bid="B53">53</abbr>
</abbrgrp>. During these times, an exogenous supply of ketones may force the brain to shift its reliance from glucose to ketones, thus taking advantage of improved transport and cellular metabolism. This shift can be advantageous in both acute brain injury models (glutamate excitotoxicity, hypoxia/ischemia, TBI) and neurodegenerative conditions (Parkinson's disease, Alzheimer's disease).</p>
<p>Extensive research has been performed using the glutamate-induced injury model, the cerebral hypoxia model and the ischemic injury model. Glutamate neurotoxicity is implicated in a number of neurodegenerative disorders associated with brain ischemia, hypoglycemia and cerebral trauma. During injury, glutamate and aspartate are released through the reverse action of their transport systems or via enhanced exocytotic release. This in turn leads to excitotoxicity and the production of reactive oxidant species. Administration of ketones appears to limit the extent of damage <abbrgrp>
<abbr bid="B54">54</abbr>
<abbr bid="B55">55</abbr>
<abbr bid="B56">56</abbr>
<abbr bid="B57">57</abbr>
<abbr bid="B58">58</abbr>
</abbrgrp>. For example, Massieu and colleagues demonstrated that AcAc effectively protects against glutamate neurotoxicity both <it>in vivo </it>and <it>in vitro </it>in rats chronically treated with a glycolysis inhibitor <abbrgrp>
<abbr bid="B55">55</abbr>
</abbrgrp>.</p>
<p>Hypoxic/ischemic injury leads to a decrease in oxidative metabolism by reducing oxygen availability <abbrgrp>
<abbr bid="B59">59</abbr>
<abbr bid="B60">60</abbr>
</abbrgrp>. Ketone administration ameliorates many of the sequelae of this process, including lactate generation, free radical damage and apoptotic cascade activation <abbrgrp>
<abbr bid="B61">61</abbr>
<abbr bid="B62">62</abbr>
</abbrgrp>. Suzuki and colleagues demonstrated that BHB prolonged the survival time in rat models of hypoxia, anoxia and global ischemia <abbrgrp>
<abbr bid="B63">63</abbr>
</abbrgrp>. They further showed that BHB reduced infarct size after middle cerebral artery occlusion, irrespective of whether BHB administration was delayed.</p>
<p>More recently, TBI models have been developed <abbrgrp>
<abbr bid="B64">64</abbr>
<abbr bid="B65">65</abbr>
</abbrgrp>. TBI is associated with impaired cerebral energy production with prolonged glucose metabolic depression and reduction of ATP. Cerebral injury is further exacerbated by free radical production, and activation of poly- ADP-ribose polymerase via DNA damage <abbrgrp>
<abbr bid="B66">66</abbr>
</abbrgrp>. As such, under these conditions of impaired glycolytic metabolism, shifting the brain toward ketone metabolism may limit the extent of cerebral injury <abbrgrp>
<abbr bid="B63">63</abbr>
<abbr bid="B67">67</abbr>
<abbr bid="B68">68</abbr>
<abbr bid="B69">69</abbr>
<abbr bid="B70">70</abbr>
</abbrgrp> (see Table <tblr tid="T1">1</tblr>). Much of this work is attributable to Prins and colleagues, who demonstrated that administration of intravenous BHB after TBI in adult rats led to an increase in uptake of BHB and alleviated the decrease in ATP after injury. In a subsequent study they found that a ketogenic diet was effective in reducing the cortical contusion volume in a rat model of TBI <abbrgrp>
<abbr bid="B64">64</abbr>
<abbr bid="B65">65</abbr>
</abbrgrp>.</p>
<tbl id="T1"><title><p>Table 1</p></title><caption><p>Animal and basic science studies on effects of ketone administration on brain injury</p></caption><tblbdy cols="5">
      <r>
         <c ca="left">
            <p>
               <b>Mechanism of injury</b>
            </p>
         </c>
         <c ca="left">
            <p>
               <b>Reference</b>
            </p>
         </c>
         <c ca="left">
            <p>
               <b>Ketone source</b>
            </p>
         </c>
         <c ca="left">
            <p>
               <b>Study</b>
            </p>
         </c>
         <c ca="left">
            <p>
               <b>Outcome</b>
            </p>
         </c>
      </r>
      <r>
         <c cspan="5">
            <hr/>
         </c>
      </r>
      <r>
         <c ca="left">
            <p>Glutamate-induced injury</p>
         </c>
         <c ca="left">
            <p>Massieu and colleagues <abbrgrp><abbr bid="B55">55</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>i.v.</p>
         </c>
         <c ca="left">
            <p>AcAc infusion for 14 days in adult rodent model prior to and during glutamate-induced injury</p>
         </c>
         <c ca="left">
            <p>Decreased neuronal damage, decreased lesion volume and increased cellular ATP levels</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Noh and colleagues <abbrgrp><abbr bid="B57">57</abbr><abbr bid="B58">58</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>p.o.</p>
         </c>
         <c ca="left">
            <p>21-day-old mice fed ketogenic diet prior to kianic-induced neuronal damage</p>
         </c>
         <c ca="left">
            <p>Preservation of neurons in hippocampus by inhibiting caspase-3-mediated apoptosis</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Mejia-Toiber and colleagues <abbrgrp><abbr bid="B56">56</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>
               <it>In vivo</it>
            </p>
         </c>
         <c ca="left">
            <p>BHB applied before glutamate-induced neurotoxicity</p>
         </c>
         <c ca="left">
            <p>BHB reduces injury and lipoperoxidation</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Maalouf and colleagues <abbrgrp><abbr bid="B54">54</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>
               <it>In vivo</it>
            </p>
         </c>
         <c ca="left">
            <p>Addition of BHB to <it>in vitro </it>model of glutamate neurotoxicity</p>
         </c>
         <c ca="left">
            <p>Reduction in free radical formation and enhanced mitochondrial respiration</p>
         </c>
      </r>
      <r>
         <c ca="left">
            <p>Cerebral hypoxia</p>
         </c>
         <c ca="left">
            <p>Puchowicz and colleagues <abbrgrp><abbr bid="B60">60</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>p.o.</p>
         </c>
         <c ca="left">
            <p>Rats fed ketogenic diet 3 weeks prior to hypoxic injury</p>
         </c>
         <c ca="left">
            <p>Decreased cerebral lactate and increased tolerance of hypoxia</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Masuda and colleagues <abbrgrp><abbr bid="B59">59</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>
               <it>In vivo</it>
            </p>
         </c>
         <c ca="left">
            <p>Rat neurons exposed to hypoxia following treatment with BHB</p>
         </c>
         <c ca="left">
            <p>Decreased cell death and number of apoptotic cells with maintenance of mitochondrial membrane</p>
         </c>
      </r>
      <r>
         <c ca="left">
            <p>Cerebral ischemia</p>
         </c>
         <c ca="left">
            <p>Suzuki and colleagues <abbrgrp><abbr bid="B70">70</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>i.v.</p>
         </c>
         <c ca="left">
            <p>Rats infused with BHB 3 to 6 hours after bilateral carotid artery occlusion</p>
         </c>
         <c ca="left">
            <p>Decreased cerebral edema and sodium content and increased ATP levels</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Suzuki and colleagues <abbrgrp><abbr bid="B63">63</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>i.v.</p>
         </c>
         <c ca="left">
            <p>BHB infusions following occlusion of the middle cerebral artery</p>
         </c>
         <c ca="left">
            <p>50% reduction in cerebral infarct volume</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Marie and colleagues <abbrgrp><abbr bid="B69">69</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>Fasted</p>
         </c>
         <c ca="left">
            <p>Adult rats fasted for 24 hours before four-vessel occlusion</p>
         </c>
         <c ca="left">
            <p>Decreased mortality, post-traumatic seizures and brain lactate</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Go and colleagues <abbrgrp><abbr bid="B68">68</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>Fasted</p>
         </c>
         <c ca="left">
            <p>Starvation-induced ketosis followed by carotid occlusion</p>
         </c>
         <c ca="left">
            <p>Fasting protected rats from brain infarction</p>
         </c>
      </r>
      <r>
         <c ca="left">
            <p>Traumatic brain injury</p>
         </c>
         <c ca="left">
            <p>Prins and colleagues <abbrgrp><abbr bid="B65">65</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>i.v.</p>
         </c>
         <c ca="left">
            <p>BHB infusion following TBI in adult rats</p>
         </c>
         <c ca="left">
            <p>Increase in serum BHB and cerebral BHB and improved cortical ATP levels</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Prins and colleagues <abbrgrp><abbr bid="B64">64</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>p.o.</p>
         </c>
         <c ca="left">
            <p>Rats with TBI fed ketogenic diet</p>
         </c>
         <c ca="left">
            <p>50% reduction in cortical contusion volume</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Biros and Nordness <abbrgrp><abbr bid="B67">67</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>p.o.</p>
         </c>
         <c ca="left">
            <p>Rats of differing ages fed ketogenic diet following TBI</p>
         </c>
         <c ca="left">
            <p>Younger rats demonstrated larger reduction in contusion volume</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Hu and colleagues <abbrgrp><abbr bid="B61">61</abbr><abbr bid="B62">62</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>p.o.</p>
         </c>
         <c ca="left">
            <p>Rats fed ketogenic diet prior to TBI</p>
         </c>
         <c ca="left">
            <p>Reduced brain edema and cellular apoptosis in rats fed ketone diet</p>
         </c>
      </r>
   </tblbdy><tblfn>
      <p>AcAc, acetoacetate; BHB, &#946;-hydroxybutyrate; <it>In vivo</it>, <it>in vivo </it>experiment; i.v., intravenous; p.o., per orally; TBI, traumatic brain injury.</p>
   </tblfn></tbl>
<p>Neurodegenerative conditions may also benefit from ketone administration as there is evidence of altered cerebral metabolism. Studies of Parkinson's disease and Alzheimer's disease confirm the encouraging effects of ketones. Mechanisms are complex but include decreasing free radical production and providing acetyl CoA for energy production <abbrgrp>
<abbr bid="B45">45</abbr>
<abbr bid="B52">52</abbr>
<abbr bid="B71">71</abbr>
<abbr bid="B72">72</abbr>
<abbr bid="B73">73</abbr>
<abbr bid="B74">74</abbr>
</abbrgrp>. Other conditions that may be responsive to ketones include amyotrophic lateral sclerosis and certain brain tumors.</p>
</sec>
<sec>
<st>
<p>Models of injury - human research</p>
</st>
<p>Mild ketosis is induced in humans by either fasting or the consumption of a high-fat, low-carbohydrate diet. Most studies in humans have delivered ketones via the enteral route <abbrgrp>
<abbr bid="B75">75</abbr>
</abbrgrp>. In adults, achieving blood levels of 5 to 7 mM/l total KB requires the production or intake of about 150 g per day <abbrgrp>
<abbr bid="B23">23</abbr>
</abbrgrp>. This level, however, is subject to the influences of glucose, insulin, cortisol and catecholamines. To achieve a therapeutic response in refractory epilepsy, it has been suggested that the level of blood ketone should be above 4 mM/l <abbrgrp>
<abbr bid="B76">76</abbr>
</abbrgrp>.</p>
<p>Salts of KB can be produced. Several authors (see below) have administered sodium AcAc or sodium BHB successfully with few side effects. A new formulation called KTX 0101 consists of a combination of NaCl and BHB, although relevant concentrations are not described <abbrgrp>
<abbr bid="B77">77</abbr>
</abbrgrp>. The main issues related to intravenous administration of ketone solutions include volume loading, sodium loading and the potential for significant metabolic alkalosis. These issues will depend on the relevant concentrations of anions and cations in the mixture and on the osmolality.</p>
<p>There is a paucity of research examining the effects of ketone administration in humans. Interpretation of results is further complicated by variable routes of administration, concentrations and age variability of research subjects. For instance, research on the effects of intraenous ketone preparations are confined almost exclusively to adults, whereas dietary studies include a large number of children. As far as we are aware, only two clinical studies examining the neuroprotective effects of KB in humans have been undertaken. The first by Ritter and colleagues examined the effects of a ketogenic diet on biochemical markers of metabolism in head-injury patients but did not include clinical outcomes <abbrgrp>
<abbr bid="B78">78</abbr>
</abbrgrp>. The second study, reported by Smith and colleagues, has never been published but the authors reported on the use of a sodium BHB solution for neuroprotection during cardiac surgery <abbrgrp>
<abbr bid="B77">77</abbr>
</abbrgrp>. The bulk of the research has taken place using the rodent model.</p>
<p>Some general statements, however, can be made. Studies have demonstrated that ketones can be given enterally or intravenously with minimal side effects; that utilization of KB increases with rising blood concentrations, with a plateau at approximately 128 g/24 hours; that hyperketotic states are associated with improved glucose control; that increased plasma levels lead to an increase in cerebral uptake; and that ketogenic diets may lead to improved cognitive function in patients with chronic dementia (see Table <tblr tid="T2">2</tblr>). Well-designed outcome studies, however, are lacking <abbrgrp>
<abbr bid="B34">34</abbr>
<abbr bid="B35">35</abbr>
<abbr bid="B77">77</abbr>
<abbr bid="B78">78</abbr>
<abbr bid="B79">79</abbr>
<abbr bid="B80">80</abbr>
<abbr bid="B81">81</abbr>
<abbr bid="B82">82</abbr>
<abbr bid="B83">83</abbr>
<abbr bid="B84">84</abbr>
<abbr bid="B85">85</abbr>
</abbrgrp>.</p>
<tbl id="T2"><title><p>Table 2</p></title><caption><p>Human studies investigating effects of exogenous ketone administration</p></caption><tblbdy cols="4">
      <r>
         <c ca="left">
            <p>
               <b>Pathophysiological endpoint</b>
            </p>
         </c>
         <c ca="left">
            <p>
               <b>Reference</b>
            </p>
         </c>
         <c ca="left">
            <p>
               <b>Study</b>
            </p>
         </c>
         <c ca="left">
            <p>
               <b>Outcome</b>
            </p>
         </c>
      </r>
      <r>
         <c cspan="4">
            <hr/>
         </c>
      </r>
      <r>
         <c ca="left">
            <p>Metabolic effects</p>
         </c>
         <c ca="left">
            <p>Owen and colleagues <abbrgrp><abbr bid="B83">83</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>Effect of ketones on insulin and free fatty acid release. Sodium AcAc given as i.v. infusion 1 mmol/kg over 2 hours to 12 normal adults after overnight fast</p>
         </c>
         <c ca="left">
            <p>AcAc levels 4.74 mmol/l after 30 minutes. Utilization of ketones increased with rising blood concentrations to a maximum of 13 g/24 hours. Glucose remained normal</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Miles and colleagues <abbrgrp><abbr bid="B82">82</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>Evaluation of protein-sparing effects of i.v. infusion of NaBHB in six healthy adults</p>
         </c>
         <c ca="left">
            <p>Ketone levels reached 2.33 mmol/l. No protein sparing, significant alkalosis</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Hiraide and colleagues <abbrgrp><abbr bid="B81">81</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>Twenty patients following severe trauma: 11 patients received i.v. 20% solution NaBHB at 25 &#956;mol/kg/minute for 3 hours, and nine patients received sodium lactate</p>
         </c>
         <c ca="left">
            <p>Ketone levels reached 1.5 mmol/l. Alanine release decreased in ketone group, suggesting a suppression of post-traumatic protein catabolism. Significant increase in sodium and pH</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Dashti and colleagues <abbrgrp><abbr bid="B80">80</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>64 healthy obese adults with and without diabetes fed ketogenic diet for 56 weeks</p>
         </c>
         <c ca="left">
            <p>Body mass index, glucose, total and low-density lipoprotein cholesterol decreased significantly whereas high-density lipoprotein increased</p>
         </c>
      </r>
      <r>
         <c ca="left">
            <p>Central nervous system effects</p>
         </c>
         <c ca="left">
            <p>Pan and colleagues <abbrgrp><abbr bid="B35">35</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>Six healthy adults infused with NaBHB at a bolus rate of 80 &#956;mol/kg/minute, then 20 &#956;mol/kg/minute for 75 minutes. BHB brain levels measured by MRI</p>
         </c>
         <c ca="left">
            <p>BHB blood levels reached 2.12 mmol/l. BHB brain levels increased to 0.24 mmol/l. Levels lower then noted in fasted individuals suggesting differences in brain transport of ketones in fasted state</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Pan and colleagues <abbrgrp><abbr bid="B34">34</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>Five healthy adults. Ketones measured in brain using MRI in nonfasted state and after 2 and 3 days of fast</p>
         </c>
         <c ca="left">
            <p>Plasma and brain BHB levels correlated well, with brain BHB ranging from 0.05 mmol/l in nonfasted state to 0.98 mmol/l after 3 days of fasting</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Blomqvist and colleagues <abbrgrp><abbr bid="B79">79</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>Six healthy and six diabetic patients received infusion of BHB at 3 to 6 mg/kg/minute for 60 minutes followed by bolus of B-[11C]HB. PET scan was performed</p>
         </c>
         <c ca="left">
            <p>Utilization rate of ketones increase proportionally with plasma concentrations. Rate-limiting step for ketone body utilization is transport into the brain</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Hasselbalch and colleagues <abbrgrp><abbr bid="B85">85</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>Permeability of blood-brain barrier to BHB was assessed following a 3.5-day fast</p>
         </c>
         <c ca="left">
            <p>Increase cerebral ketone influx during starvation determined by amount of ketone present in blood</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Ritter and colleagues <abbrgrp><abbr bid="B78">78</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>Twenty head-injured patients assigned to conventional or ketogenic diet for 2 weeks</p>
         </c>
         <c ca="left">
            <p>Group receiving a ketogenic diet demonstrated improved glucose control with higher ketone levels. Cerebral lactate was similar</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Smith and colleagues <abbrgrp><abbr bid="B77">77</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>NaBHB i.v. solution known as KTX 0101 for neuroprotection post CABG. Details of study protocol not available</p>
         </c>
         <c ca="left">
            <p>Phase Ia study not published</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Hasselbalch and colleagues <abbrgrp><abbr bid="B50">50</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>Eight healthy adults received i.v. infusion of NaBHB at 4 to 5 mg/kg/minute for 3 hours. Cerebral blood flow measured using Kety-Schmidt technique</p>
         </c>
         <c ca="left">
            <p>Increased cerebral uptake of ketones was counterbalanced by reduction in glucose metabolism. Cerebral metabolic rate was unchanged, but cerebral blood flow increased</p>
         </c>
      </r>
      <r>
         <c>
            <p/>
         </c>
         <c ca="left">
            <p>Reger and colleagues <abbrgrp><abbr bid="B84">84</abbr></abbrgrp></p>
         </c>
         <c ca="left">
            <p>Twenty adults with Alzheimer's disease were randomized to receive a MCT diet or placebo on two occasions</p>
         </c>
         <c ca="left">
            <p>On cognitive testing, MCT treatment facilitated performance for &#949;4-negative but not &#949;4-positive subjects. Also greater improvement with MCT treatment relative to placebo</p>
         </c>
      </r>
   </tblbdy><tblfn>
      <p>AcAc, acetoacetate; B-[11C]HB, R-&#946;-[1-11C]hydroxybutyrate; BHB, &#946;-hydroxybutyrate; CABG, coronary artery bypass graft; i.v., intravenous; MCT, medium chain triglycerides; MRI, magnetic resonance imaging; NaBHB, sodium &#946;-hydroxybutyrate; PET, positron emission tomography.</p>
   </tblfn></tbl>
</sec>
<sec>
<st>
<p>Adverse effects of ketones</p>
</st>
<p>There are minimal data on the adverse effects of ketone administration, much of which are based on chronic intake via the enteral route rather than the parenteral route. In the acute setting, effects of parenteral formulations on the pH, sodium level, lipids and glucose are likely to dominate; for example, intravenous formulations would theoretically be alkalinizing, depending on the ketone concentration. This was confirmed by Hiraide and colleagues, who noted a significant increase in pH and sodium concentrations following the intravenous administration of a 20% solution of sodium BHB to severe trauma patients <abbrgrp>
<abbr bid="B81">81</abbr>
</abbrgrp>. Also of potential concern is the reduction in glucose cerebral metabolism and the increase in cerebral blood flow demonstrated by Hasselbalch and colleagues during administration of intravenous BHB <abbrgrp>
<abbr bid="B50">50</abbr>
</abbrgrp>. The long-term consequences of these changes are not yet known.</p>
<p>Some side effects are predictable following enteral administration, such as dehydration and hypoglycemia. Other side effects are less common and present following prolonged use, including growth retardation, obesity, nutrient deficiency, decreased bone density, hepatic failure, and immune dysfunction. Freeman and colleagues reported a significant rise in mean blood cholesterol to over 250 mg/dl following prolonged intake a of ketogenic diet <abbrgrp>
<abbr bid="B86">86</abbr>
</abbrgrp>. This effect in turn may be atherogenic, leading to lipid deposition in blood vessels. In addition there are reports of dilated cardiomyopathy in patients on the ketogenic diet, possibly as a consequence of the toxic effects of elevated plasma free fatty acids. Finally, an increased incidence in nephrolithiasis in patients on the ketogenic diet as well as increases in serum uric acid secondary have been reported <abbrgrp>
<abbr bid="B66">66</abbr>
<abbr bid="B87">87</abbr>
</abbrgrp>.</p>
</sec>
</sec>
<sec>
<st>
<p>Potential clinical applications for ketone solutions - traumatic brain injury</p>
</st>
<p>TBI is a major cause of mortality and morbidity in young adults <abbrgrp>
<abbr bid="B88">88</abbr>
</abbrgrp>. Cerebral edema and subsequent intracranial hypertension is an important factor influencing patient outcome, and, despite considerable research, has proven difficult to manage. Over the past 30 years, osmotherapy has become an important tool in the management of intracranial hypertension after TBI <abbrgrp>
<abbr bid="B88">88</abbr>
</abbrgrp>. Various substances, including urea, glycerol, sorbitol and mannitol, have been utilized <abbrgrp>
<abbr bid="B89">89</abbr>
<abbr bid="B90">90</abbr>
</abbrgrp>. More recently, hypertonic saline (HTS) has proven useful in controlling intracranial pressure (ICP).</p>
<p>HTS has been extensively studied in animal and human models of TBI <abbrgrp>
<abbr bid="B91">91</abbr>
<abbr bid="B92">92</abbr>
<abbr bid="B93">93</abbr>
<abbr bid="B94">94</abbr>
</abbrgrp>. These experiments suggest that small-volume resuscitation with HTS solution may be beneficial for increasing cerebral perfusion pressure and cerebral blood flow and for decreasing ICP while maintaining hemodynamic stability following TBI. Animal studies comparing HTS and mannitol suggest that HTS is more effective in reducing ICP and has a longer duration of action <abbrgrp>
<abbr bid="B95">95</abbr>
<abbr bid="B96">96</abbr>
</abbrgrp>. In humans, HTS appears effective for reducing ICP in cases of refractory intracranial hyper- tension following TBI. Several studies have confirmed a significant decrease in ICP correlated with an increasing serum osmolality <abbrgrp>
<abbr bid="B97">97</abbr>
<abbr bid="B98">98</abbr>
<abbr bid="B99">99</abbr>
</abbrgrp>.</p>
<p>In the past, researchers have combined hypertonic sodium with a variety of anions including acetate and lactate <abbrgrp>
<abbr bid="B100">100</abbr>
<abbr bid="B101">101</abbr>
</abbrgrp>. Acetate, a source of hydrogen ion acceptors, is an alternate source of bicarbonate by metabolic conversion in the liver. Acetate is a myocardial depressant, however, and can lead to hypotension in susceptible individuals. Hypertonic sodium/lactate solutions have also been investigated. Whilst HTS/lactate is generally considered safe and may provide cerebral nutrition, there are limited animal data suggesting that fluids containing lactate may be associated with significant toxic effects <abbrgrp>
<abbr bid="B102">102</abbr>
</abbrgrp>. Further research is required to clarify these issues.</p>
<p>There is therefore a need for a solution able to address two fundamental problems related to TBI; namely, refractory intracerebral hypertension and low cerebral energy levels. This requirement could theoretically be accomplished by incorporating ketones into a hypertonic solution such as HTS. There are, however, a number of challenges associated with the development of new parenteral solutions.</p>
<p>Firstly, the impact of the constituents on individual metabolism needs to be evaluated. The hypertonicity induced by 3% NaCl is well documented and desirable. The target sodium level is not known, however, and various authors have reported levels as high as 185 mmol/l. Secondly, although the long-term metabolic effects of ketone administration are described, little information exists on the acute changes induced by intravenous infusions. For example, the entry of ketones into cerebrospinal fluid is partly concentration dependent and therefore a certain serum level (possibly above 4 mM/l) is required for maximum utilization. What then is the effect of high ketone concentration on blood pH? Such a solution would be expected to be alkalinizing, but this will be altered by the rate of metabolism. Thirdly, which ketone should be incorporated, AcAc or BHB? Both ketones have been administered to humans in the past without ill effects. Fourthly, should cerebrospinal fluid or plasma levels be utilized to guide therapy? Lastly, ketones are expensive to produce, so can a commercially viable solution be developed?</p>
</sec>
<sec>
<st>
<p>Conclusion</p>
</st>
<p>There is both theoretical and clinical evidence that administering ketones to patients with cerebral injury may provide significant benefit. Furthermore, combining ketones with HTS may provide the added advantage of ICP control with improved cerebral metabolism. There are, however, a number of outstanding questions requiring further consideration. These questions include dosing, timing, and the route and duration of administration. Further research is necessary to clarify these issues and to determine whether an HTS ketone solution could be employed in the management of acute brain injury.</p>
</sec>
<sec>
<st>
<p>Abbreviations</p>
</st>
<p>AcAc: acetoacetate; acetyl CoA: coenzyme A; AKBR: arterial ketone body ratio; BBB: blood-brain barrier; BHB: &#946;-hydroxybutyrate; BHD: &#946;-hydroxybutyrate dehydrogenase; GABA: &#947;-aminobutyric acid; HTS: hypertonic saline; ICP: intracranial pressure; KB: ketone bodies; MCT: monocarboxylic acid transporter; NAD<sup>+</sup>: nicotinamide adenine dinucleotide; NADH: nicotinamide adenine dinucleotide hydrogenase; TBI: traumatic brain injury.</p>
</sec>
<sec>
<st>
<p>Competing interests</p>
</st>
<p>The authors declare that they have no competing interests.</p>
</sec>
</bdy><bm>
<refgrp><bibl id="B1"><title><p>Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry</p></title><aug><au><snm>Fukao</snm><fnm>T</fnm></au><au><snm>Lopaschuk</snm><fnm>GD</fnm></au><au><snm>Mitchell</snm><fnm>GA</fnm></au></aug><source>Prostaglandins Leukot Essent Fatty Acids</source><pubdate>2004</pubdate><volume>70</volume><fpage>243</fpage><lpage>251</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/j.plefa.2003.11.001</pubid><pubid idtype="pmpid" link="fulltext">14769483</pubid></pubidlist></xrefbib></bibl><bibl id="B2"><title><p>Regulation of intermediary metabolism during fasting and feeding</p></title><aug><au><snm>DeFronzo</snm><fnm>R</fnm></au><au><snm>Ferrannini</snm><fnm>E</fnm></au></aug><source>Endocrinology</source><publisher>Philadelphia: W.B. Saunders</publisher><editor>DeGroot L, Jameson J</editor><pubdate>2001</pubdate><fpage>737</fpage><lpage>755</lpage></bibl><bibl id="B3"><title><p>The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism</p></title><aug><au><snm>Veech</snm><fnm>RL</fnm></au></aug><source>Prostaglandins Leukot Essent Fatty Acids</source><pubdate>2004</pubdate><volume>70</volume><fpage>309</fpage><lpage>319</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/j.plefa.2003.09.007</pubid><pubid idtype="pmpid" link="fulltext">14769489</pubid></pubidlist></xrefbib></bibl><bibl id="B4"><title><p>The redox state of free nicotinamideadenine dinucleotide in the cytoplasm and mitochondria of rat liver</p></title><aug><au><snm>Williamson</snm><fnm>DH</fnm></au><au><snm>Lund</snm><fnm>P</fnm></au><au><snm>Krebs</snm><fnm>HA</fnm></au></aug><source>Biochem J</source><pubdate>1967</pubdate><volume>103</volume><fpage>514</fpage><lpage>527</lpage><xrefbib><pubidlist><pubid idtype="pmcid">1270436</pubid><pubid idtype="pmpid">4291787</pubid></pubidlist></xrefbib></bibl><bibl id="B5"><title><p>The redox state of free nicotinamideadenine dinucleotide phosphate in the cytoplasm of rat liver</p></title><aug><au><snm>Veech</snm><fnm>RL</fnm></au><au><snm>Eggleston</snm><fnm>LV</fnm></au><au><snm>Krebs</snm><fnm>HA</fnm></au></aug><source>Biochem J</source><pubdate>1969</pubdate><volume>115</volume><fpage>609</fpage><lpage>619</lpage><xrefbib><pubidlist><pubid idtype="pmcid">1185185</pubid><pubid idtype="pmpid">4391039</pubid></pubidlist></xrefbib></bibl><bibl id="B6"><title><p>The fasting test in paediatrics: application to the diagnosis of pathological hypo- and hyperketotic states</p></title><aug><au><snm>Bonnefont</snm><fnm>JP</fnm></au><au><snm>Specola</snm><fnm>NB</fnm></au><au><snm>Vassault</snm><fnm>A</fnm></au><au><snm>Lombes</snm><fnm>A</fnm></au><au><snm>Ogier</snm><fnm>H</fnm></au><au><snm>de Klerk</snm><fnm>JB</fnm></au><au><snm>Munnich</snm><fnm>A</fnm></au><au><snm>Coude</snm><fnm>M</fnm></au><au><snm>Paturneau-Jouas</snm><fnm>M</fnm></au><au><snm>Saudubray</snm><fnm>JM</fnm></au></aug><source>Eur J Pediatr</source><pubdate>1990</pubdate><volume>150</volume><fpage>80</fpage><lpage>85</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/BF02072043</pubid><pubid idtype="pmpid">2279514</pubid></pubidlist></xrefbib></bibl><bibl id="B7"><title><p>Hormone-fuel interrelationships during fasting</p></title><aug><au><snm>Cahill</snm><fnm>GF</fnm></au><au><snm>Herrera</snm><fnm>MG</fnm></au><au><snm>Morgan</snm><fnm>AP</fnm></au><au><snm>Soeldner</snm><fnm>JS</fnm></au><au><snm>Steinke</snm><fnm>J</fnm></au><au><snm>Levy</snm><fnm>PL</fnm></au><au><snm>Reichard</snm><fnm>GA</fnm></au><au><snm>Kipnis</snm><fnm>DM</fnm></au></aug><source>J Clin Invest</source><pubdate>1966</pubdate><volume>45</volume><fpage>1751</fpage><lpage>1769</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1172/JCI105481</pubid><pubid idtype="pmcid">292859</pubid><pubid idtype="pmpid">5926444</pubid></pubidlist></xrefbib></bibl><bibl id="B8"><title><p>Liver and kidney metabolism during prolonged starvation</p></title><aug><au><snm>Owen</snm><fnm>OE</fnm></au><au><snm>Felig</snm><fnm>P</fnm></au><au><snm>Morgan</snm><fnm>AP</fnm></au><au><snm>Wahren</snm><fnm>J</fnm></au><au><snm>Cahill</snm><fnm>GF</fnm><suf>Jr</suf></au></aug><source>J Clin Invest</source><pubdate>1969</pubdate><volume>48</volume><fpage>574</fpage><lpage>583</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1172/JCI106016</pubid><pubid idtype="pmcid">535723</pubid><pubid idtype="pmpid">5773093</pubid></pubidlist></xrefbib></bibl><bibl id="B9"><title><p>Hepatic ketogenesis and gluconeogenesis in humans</p></title><aug><au><snm>Garber</snm><fnm>AJ</fnm></au><au><snm>Menzel</snm><fnm>PH</fnm></au><au><snm>Boden</snm><fnm>G</fnm></au><au><snm>Owen</snm><fnm>OE</fnm></au></aug><source>J Clin Invest</source><pubdate>1974</pubdate><volume>54</volume><fpage>981</fpage><lpage>989</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1172/JCI107839</pubid><pubid idtype="pmcid">301639</pubid><pubid idtype="pmpid">4430728</pubid></pubidlist></xrefbib></bibl><bibl id="B10"><title><p>Ketone body production and metabolism in the fetus and newborn</p></title><aug><au><snm>Williamson</snm><fnm>DH</fnm></au></aug><source>Neonatal Physiology</source><publisher>Philadelphia: W.B. Saunders</publisher><editor>Polin R, Fox W</editor><pubdate>1992</pubdate><fpage>330</fpage><lpage>340</lpage></bibl><bibl id="B11"><title><p>Ketone body production and disposal: effects of fasting, diabetes, and exercise</p></title><aug><au><snm>Balasse</snm><fnm>EO</fnm></au><au><snm>Fery</snm><fnm>F</fnm></au></aug><source>Diabetes Metab Rev</source><pubdate>1989</pubdate><volume>5</volume><fpage>247</fpage><lpage>270</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/dmr.5610050304</pubid><pubid idtype="pmpid">2656155</pubid></pubidlist></xrefbib></bibl><bibl id="B12"><title><p>Uptake of ketone bodies by rat brain in vivo</p></title><aug><au><snm>Hawkins</snm><fnm>RA</fnm></au></aug><source>Biochem J</source><pubdate>1971</pubdate><volume>121</volume><fpage>17P</fpage><xrefbib><pubidlist><pubid idtype="pmcid">1176528</pubid><pubid idtype="pmpid">5116532</pubid></pubidlist></xrefbib></bibl><bibl id="B13"><title><p>Activities of enzymes involved in acetoacetate utilization in adult mammalian tissues</p></title><aug><au><snm>Williamson</snm><fnm>DH</fnm></au><au><snm>Bates</snm><fnm>MW</fnm></au><au><snm>Page</snm><fnm>MA</fnm></au><au><snm>Krebs</snm><fnm>HA</fnm></au></aug><source>Biochem J</source><pubdate>1971</pubdate><volume>121</volume><fpage>41</fpage><lpage>47</lpage><xrefbib><pubidlist><pubid idtype="pmcid">1176484</pubid><pubid idtype="pmpid">5165621</pubid></pubidlist></xrefbib></bibl><bibl id="B14"><title><p>Mitochondrial function in sepsis: acute phase versus multiple organ failure</p></title><aug><au><snm>Singer</snm><fnm>M</fnm></au></aug><source>Crit Care Med</source><pubdate>2007</pubdate><volume>35</volume><fpage>S441</fpage><lpage>S448</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1097/01.CCM.0000278049.48333.78</pubid><pubid idtype="pmpid" link="fulltext">17713391</pubid></pubidlist></xrefbib></bibl><bibl id="B15"><title><p>Mitochondrial redox state in the critically ill</p></title><aug><au><snm>Yassen</snm><fnm>KA</fnm></au><au><snm>Galley</snm><fnm>HF</fnm></au><au><snm>Lee</snm><fnm>A</fnm></au><au><snm>Webster</snm><fnm>NR</fnm></au></aug><source>Br J Anaesth</source><pubdate>1999</pubdate><volume>83</volume><fpage>325</fpage><lpage>327</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">10618950</pubid></xrefbib></bibl><bibl id="B16"><title><p>Superoxide production by liver macrophages in septic shock model - relation to arterial ketone body ratio</p></title><aug><au><snm>Limuro</snm><fnm>Y</fnm></au><au><snm>Yamamoto</snm><fnm>M</fnm></au><au><snm>Inoue</snm><fnm>S</fnm></au><au><snm>Kohno</snm><fnm>H</fnm></au><au><snm>Matsumoto</snm><fnm>Y</fnm></au></aug><source>Eur Surg Res</source><pubdate>1992</pubdate><volume>24</volume><fpage>363</fpage><lpage>371</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1159/000129229</pubid><pubid idtype="pmpid">1338046</pubid></pubidlist></xrefbib></bibl><bibl id="B17"><title><p>Real-time assessment of hepatic function is related to clinical outcome in critically ill patients after polytrauma</p></title><aug><au><snm>Dresing</snm><fnm>K</fnm></au><au><snm>Armstrong</snm><fnm>VW</fnm></au><au><snm>Leip</snm><fnm>CL</fnm></au><au><snm>Streit</snm><fnm>F</fnm></au><au><snm>Burchardi</snm><fnm>H</fnm></au><au><snm>Sturmer</snm><fnm>KM</fnm></au><au><snm>Oellerich</snm><fnm>M</fnm></au></aug><source>Clin Biochem</source><pubdate>2007</pubdate><volume>40</volume><fpage>1194</fpage><lpage>1200</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/j.clinbiochem.2007.06.013</pubid><pubid idtype="pmpid" link="fulltext">17707362</pubid></pubidlist></xrefbib></bibl><bibl id="B18"><title><p>Evolution of lactate/pyruvate and arterial ketone body ratios in the early course of catecholamine-treated septic shock</p></title><aug><au><snm>Levy</snm><fnm>B</fnm></au><au><snm>Sadoune</snm><fnm>LO</fnm></au><au><snm>Gelot</snm><fnm>AM</fnm></au><au><snm>Bollaert</snm><fnm>PE</fnm></au><au><snm>Nabet</snm><fnm>P</fnm></au><au><snm>Larcan</snm><fnm>A</fnm></au></aug><source>Crit Care Med</source><pubdate>2000</pubdate><volume>28</volume><fpage>114</fpage><lpage>119</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1097/00003246-200001000-00019</pubid><pubid idtype="pmpid" link="fulltext">10667509</pubid></pubidlist></xrefbib></bibl><bibl id="B19"><title><p>How astrocytes feed hungry neurons</p></title><aug><au><snm>Pellerin</snm><fnm>L</fnm></au></aug><source>Mol Neurobiol</source><pubdate>2005</pubdate><volume>32</volume><fpage>59</fpage><lpage>72</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1385/MN:32:1:059</pubid><pubid idtype="pmpid" link="fulltext">16077184</pubid></pubidlist></xrefbib></bibl><bibl id="B20"><title><p>Brain metabolism during fasting</p></title><aug><au><snm>Owen</snm><fnm>OE</fnm></au><au><snm>Morgan</snm><fnm>AP</fnm></au><au><snm>Kemp</snm><fnm>HG</fnm></au><au><snm>Sullivan</snm><fnm>JM</fnm></au><au><snm>Herrera</snm><fnm>MG</fnm></au><au><snm>Cahill</snm><fnm>GF</fnm><suf>Jr</suf></au></aug><source>J Clin Invest</source><pubdate>1967</pubdate><volume>46</volume><fpage>1589</fpage><lpage>1595</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1172/JCI105650</pubid><pubid idtype="pmcid">292907</pubid><pubid idtype="pmpid">6061736</pubid></pubidlist></xrefbib></bibl><bibl id="B21"><title><p>The metabolism of acetone in rat</p></title><aug><au><snm>Casazza</snm><fnm>JP</fnm></au><au><snm>Felver</snm><fnm>ME</fnm></au><au><snm>Veech</snm><fnm>RL</fnm></au></aug><source>J Biol Chem</source><pubdate>1984</pubdate><volume>259</volume><fpage>231</fpage><lpage>236</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">6706932</pubid></xrefbib></bibl><bibl id="B22"><title><p>Ketones: metabolism's ugly duckling</p></title><aug><au><snm>VanItallie</snm><fnm>TB</fnm></au><au><snm>Nufert</snm><fnm>TH</fnm></au></aug><source>Nutr Rev</source><pubdate>2003</pubdate><volume>61</volume><fpage>327</fpage><lpage>341</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1301/nr.2003.oct.327-341</pubid><pubid idtype="pmpid" link="fulltext">14604265</pubid></pubidlist></xrefbib></bibl><bibl id="B23"><title><p>Ketone-body production and oxidation in fasting obese humans</p></title><aug><au><snm>Reichard</snm><fnm>GA</fnm></au><au><snm>Owen</snm><fnm>OE</fnm></au><au><snm>Haff</snm><fnm>AC</fnm></au><au><snm>Paul</snm><fnm>P</fnm></au><au><snm>Bortz</snm><fnm>WM</fnm></au></aug><source>J Clin Invest</source><pubdate>1974</pubdate><volume>53</volume><fpage>508</fpage><lpage>515</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1172/JCI107584</pubid><pubid idtype="pmcid">301493</pubid><pubid idtype="pmpid">11344564</pubid></pubidlist></xrefbib></bibl><bibl id="B24"><title><p>Ketone body synthesis in the brain: possible neuroprotective effects</p></title><aug><au><snm>Guzman</snm><fnm>M</fnm></au><au><snm>Blazquez</snm><fnm>C</fnm></au></aug><source>Prostaglandins Leukot Essent Fatty Acids</source><pubdate>2004</pubdate><volume>70</volume><fpage>287</fpage><lpage>292</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/j.plefa.2003.05.001</pubid><pubid idtype="pmpid" link="fulltext">14769487</pubid></pubidlist></xrefbib></bibl><bibl id="B25"><title><p>Fatty acid oxidation and ketogenesis by astrocytes in primary culture</p></title><aug><au><snm>Auestad</snm><fnm>N</fnm></au><au><snm>Korsak</snm><fnm>RA</fnm></au><au><snm>Morrow</snm><fnm>JW</fnm></au><au><snm>Edmond</snm><fnm>J</fnm></au></aug><source>J Neurochem</source><pubdate>1991</pubdate><volume>56</volume><fpage>1376</fpage><lpage>1386</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1111/j.1471-4159.1991.tb11435.x</pubid><pubid idtype="pmpid">2002348</pubid></pubidlist></xrefbib></bibl><bibl id="B26"><title><p>Generation of ketone bodies from leucine by cultured astroglial cells</p></title><aug><au><snm>Bixel</snm><fnm>MG</fnm></au><au><snm>Hamprecht</snm><fnm>B</fnm></au></aug><source>J Neurochem</source><pubdate>1995</pubdate><volume>65</volume><fpage>2450</fpage><lpage>2461</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1046/j.1471-4159.1995.65062450.x</pubid><pubid idtype="pmpid" link="fulltext">7595539</pubid></pubidlist></xrefbib></bibl><bibl id="B27"><title><p>Lipoproteins in the central nervous system</p></title><aug><au><snm>Ladu</snm><fnm>MJ</fnm></au><au><snm>Reardon</snm><fnm>C</fnm></au><au><snm>Van Eldik</snm><fnm>L</fnm></au><au><snm>Fagan</snm><fnm>AM</fnm></au><au><snm>Bu</snm><fnm>G</fnm></au><au><snm>Holtzman</snm><fnm>D</fnm></au><au><snm>Getz</snm><fnm>GS</fnm></au></aug><source>Ann N Y Acad Sci</source><pubdate>2000</pubdate><volume>903</volume><fpage>167</fpage><lpage>175</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1111/j.1749-6632.2000.tb06365.x</pubid><pubid idtype="pmpid" link="fulltext">10818504</pubid></pubidlist></xrefbib></bibl><bibl id="B28"><title><p>Acetoacetate and glucose as lipid precursors and energy substrates in primary cultures of astrocytes and neurons from mouse cerebral cortex</p></title><aug><au><snm>Lopes-Cardozo</snm><fnm>M</fnm></au><au><snm>Larsson</snm><fnm>OM</fnm></au><au><snm>Schousboe</snm><fnm>A</fnm></au></aug><source>J Neurochem</source><pubdate>1986</pubdate><volume>46</volume><fpage>773</fpage><lpage>778</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1111/j.1471-4159.1986.tb13039.x</pubid><pubid idtype="pmpid">3081684</pubid></pubidlist></xrefbib></bibl><bibl id="B29"><title><p>Is there an astrocyte-neuron ketone body shuttle?</p></title><aug><au><snm>Guzman</snm><fnm>M</fnm></au><au><snm>Blazquez</snm><fnm>C</fnm></au></aug><source>Trends Endocrinol Metab</source><pubdate>2001</pubdate><volume>12</volume><fpage>169</fpage><lpage>173</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/S1043-2760(00)00370-2</pubid><pubid idtype="pmpid" link="fulltext">11295573</pubid></pubidlist></xrefbib></bibl><bibl id="B30"><title><p>Expression of monocarboxylate transporter mRNAs in mouse brain: support for a distinct role of lactate as an energy substrate for the neonatal vs. adult brain</p></title><aug><au><snm>Pellerin</snm><fnm>L</fnm></au><au><snm>Pellegri</snm><fnm>G</fnm></au><au><snm>Martin</snm><fnm>JL</fnm></au><au><snm>Magistretti</snm><fnm>PJ</fnm></au></aug><source>Proc Natl Acad Sci USA</source><pubdate>1998</pubdate><volume>95</volume><fpage>3990</fpage><lpage>3995</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1073/pnas.95.7.3990</pubid><pubid idtype="pmcid">19950</pubid><pubid idtype="pmpid">9520480</pubid></pubidlist></xrefbib></bibl><bibl id="B31"><title><p>Neurolgia: quantitative aspects</p></title><aug><au><snm>Pope</snm><fnm>A</fnm></au></aug><source>Dynamic Properties of Glial Cells: An Interdisciplinary Approach to their Study in the Central and Peripheral Nervous System</source><publisher>New York: Pergamon Press</publisher><editor>Schoff eniels E, Tower F</editor><pubdate>1978</pubdate><fpage>13</fpage><lpage>20</lpage></bibl><bibl id="B32"><title><p>Diet-induced ketosis increases monocarboxylate transporter (MCT1) levels in rat brain</p></title><aug><au><snm>Leino</snm><fnm>RL</fnm></au><au><snm>Gerhart</snm><fnm>DZ</fnm></au><au><snm>Duelli</snm><fnm>R</fnm></au><au><snm>Enerson</snm><fnm>BE</fnm></au><au><snm>Drewes</snm><fnm>LR</fnm></au></aug><source>Neurochem Int</source><pubdate>2001</pubdate><volume>38</volume><fpage>519</fpage><lpage>527</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/S0197-0186(00)00102-9</pubid><pubid idtype="pmpid" link="fulltext">11248400</pubid></pubidlist></xrefbib></bibl><bibl id="B33"><title><p>Brain metabolism during short-term starvation in humans</p></title><aug><au><snm>Hasselbalch</snm><fnm>SG</fnm></au><au><snm>Knudsen</snm><fnm>GM</fnm></au><au><snm>Jakobsen</snm><fnm>J</fnm></au><au><snm>Hageman</snm><fnm>LP</fnm></au><au><snm>Holm</snm><fnm>S</fnm></au><au><snm>Paulson</snm><fnm>OB</fnm></au></aug><source>J Cereb Blood Flow Metab</source><pubdate>1994</pubdate><volume>14</volume><fpage>125</fpage><lpage>131</lpage><xrefbib><pubid idtype="pmpid">8263048</pubid></xrefbib></bibl><bibl id="B34"><title><p>Human brain beta-hydroxybutyrate and lactate increase in fasting-induced ketosis</p></title><aug><au><snm>Pan</snm><fnm>JW</fnm></au><au><snm>Rothman</snm><fnm>TL</fnm></au><au><snm>Behar</snm><fnm>KL</fnm></au><au><snm>Stein</snm><fnm>DT</fnm></au><au><snm>Hetherington</snm><fnm>HP</fnm></au></aug><source>J Cereb Blood Flow Metab</source><pubdate>2000</pubdate><volume>20</volume><fpage>1502</fpage><lpage>1507</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1097/00004647-200010000-00012</pubid><pubid idtype="pmpid" link="fulltext">11043913</pubid></pubidlist></xrefbib></bibl><bibl id="B35"><title><p>Measurement of beta-hydroxybutyrate in acute hyperketonemia in human brain</p></title><aug><au><snm>Pan</snm><fnm>JW</fnm></au><au><snm>Telang</snm><fnm>FW</fnm></au><au><snm>Lee</snm><fnm>JH</fnm></au><au><snm>de Graaf</snm><fnm>RA</fnm></au><au><snm>Rothman</snm><fnm>DL</fnm></au><au><snm>Stein</snm><fnm>DT</fnm></au><au><snm>Hetherington</snm><fnm>HP</fnm></au></aug><source>J Neurochem</source><pubdate>2001</pubdate><volume>79</volume><fpage>539</fpage><lpage>544</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1046/j.1471-4159.2001.00575.x</pubid><pubid idtype="pmpid" link="fulltext">11701757</pubid></pubidlist></xrefbib></bibl><bibl id="B36"><title><p>Metabolic control of the expression of mitochondrial D-beta-hydroxybutyrate dehydrogenase, a ketone body converting enzyme</p></title><aug><au><snm>Kante</snm><fnm>A</fnm></au><au><snm>Cherkaoui Malki</snm><fnm>M</fnm></au><au><snm>Coquard</snm><fnm>C</fnm></au><au><snm>Latruffe</snm><fnm>N</fnm></au></aug><source>Biochim Biophys Acta</source><pubdate>1990</pubdate><volume>1033</volume><fpage>291</fpage><lpage>297</lpage><xrefbib><pubid idtype="pmpid">2317505</pubid></xrefbib></bibl><bibl id="B37"><title><p>Induction of brain D(-)-betahydroxybytrate dehydrogenase activity by fasting</p></title><aug><au><snm>Smith</snm><fnm>AL</fnm></au><au><snm>Satterthwaite</snm><fnm>HS</fnm></au><au><snm>Sokoloff</snm><fnm>L</fnm></au></aug><source>Science</source><pubdate>1969</pubdate><volume>163</volume><fpage>79</fpage><lpage>81</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1126/science.163.3862.79</pubid><pubid idtype="pmpid" link="fulltext">4975341</pubid></pubidlist></xrefbib></bibl><bibl id="B38"><title><p>Induction processes in blood-brain transfer of ketone Bodies during starvation</p></title><aug><au><snm>Gjedde</snm><fnm>A</fnm></au><au><snm>Crone</snm><fnm>C</fnm></au></aug><source>Am J Physiol</source><pubdate>1975</pubdate><volume>229</volume><fpage>1165</fpage><lpage>1169</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">1200135</pubid></xrefbib></bibl><bibl id="B39"><title><p>Beta-hydroxybutyrate transport in rat brain: developmental and dietary modulations</p></title><aug><au><snm>Moore</snm><fnm>TJ</fnm></au><au><snm>Lione</snm><fnm>AP</fnm></au><au><snm>Sugden</snm><fnm>MC</fnm></au><au><snm>Regen</snm><fnm>DM</fnm></au></aug><source>Am J Physiol</source><pubdate>1976</pubdate><volume>230</volume><fpage>619</fpage><lpage>630</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">1266963</pubid></xrefbib></bibl><bibl id="B40"><title><p>Regional ketone body utilization by rat brain in starvation and diabetes</p></title><aug><au><snm>Hawkins</snm><fnm>RA</fnm></au><au><snm>Mans</snm><fnm>AM</fnm></au><au><snm>Davis</snm><fnm>DW</fnm></au></aug><source>Am J Physiol</source><pubdate>1986</pubdate><volume>250</volume><fpage>E169</fpage><lpage>E178</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">2937307</pubid></xrefbib></bibl><bibl id="B41"><title><p>Cerebral ketone body metabolism</p></title><aug><au><snm>Morris</snm><fnm>AA</fnm></au></aug><source>J Inherit Metab Dis</source><pubdate>2005</pubdate><volume>28</volume><fpage>109</fpage><lpage>121</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/s10545-005-5518-0</pubid><pubid idtype="pmpid" link="fulltext">15877199</pubid></pubidlist></xrefbib></bibl><bibl id="B42"><title><p>Ketone bodies are selectively used by individual brain regions</p></title><aug><au><snm>Hawkins</snm><fnm>RA</fnm></au><au><snm>Biebuyck</snm><fnm>JF</fnm></au></aug><source>Science</source><pubdate>1979</pubdate><volume>205</volume><fpage>325</fpage><lpage>327</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1126/science.451608</pubid><pubid idtype="pmpid" link="fulltext">451608</pubid></pubidlist></xrefbib></bibl><bibl id="B43"><title><p>Cerebral metabolic adaptation and ketone metabolism after brain injury</p></title><aug><au><snm>Prins</snm><fnm>ML</fnm></au></aug><source>J Cereb Blood Flow Metab</source><pubdate>2008</pubdate><volume>28</volume><fpage>1</fpage><lpage>16</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1038/sj.jcbfm.9600543</pubid><pubid idtype="pmcid">2857668</pubid><pubid idtype="pmpid">17684514</pubid></pubidlist></xrefbib></bibl><bibl id="B44"><title><p>Ketone bodies, potential therapeutic uses</p></title><aug><au><snm>Veech</snm><fnm>RL</fnm></au><au><snm>Chance</snm><fnm>B</fnm></au><au><snm>Kashiwaya</snm><fnm>Y</fnm></au><au><snm>Lardy</snm><fnm>HA</fnm></au><au><snm>Cahill</snm><fnm>GF</fnm><suf>Jr</suf></au></aug><source>IUBMB Life</source><pubdate>2001</pubdate><volume>51</volume><fpage>241</fpage><lpage>247</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1080/152165401753311780</pubid><pubid idtype="pmpid" link="fulltext">11569918</pubid></pubidlist></xrefbib></bibl><bibl id="B45"><title><p>Control of glucose utilization in working perfused rat heart</p></title><aug><au><snm>Kashiwaya</snm><fnm>Y</fnm></au><au><snm>Sato</snm><fnm>K</fnm></au><au><snm>Tsuchiya</snm><fnm>N</fnm></au><au><snm>Thomas</snm><fnm>S</fnm></au><au><snm>Fell</snm><fnm>DA</fnm></au><au><snm>Veech</snm><fnm>RL</fnm></au><au><snm>Passonneau</snm><fnm>JV</fnm></au></aug><source>J Biol Chem</source><pubdate>1994</pubdate><volume>269</volume><fpage>25502</fpage><lpage>25514</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">7929251</pubid></xrefbib></bibl><bibl id="B46"><title><p>Equilibrium relations between pyridine nucleotides and adenine nucleotides and their roles in the regulation of metabolic processes</p></title><aug><au><snm>Krebs</snm><fnm>HA</fnm></au><au><snm>Veech</snm><fnm>RL</fnm></au></aug><source>Adv Enzyme Regul</source><pubdate>1969</pubdate><volume>7</volume><fpage>397</fpage><lpage>413</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/0065-2571(69)90030-2</pubid><pubid idtype="pmpid">4391643</pubid></pubidlist></xrefbib></bibl><bibl id="B47"><title><p>Ketogenic diet increases glutathione peroxidase activity in rat hippocampus</p></title><aug><au><snm>Ziegler</snm><fnm>DR</fnm></au><au><snm>Ribeiro</snm><fnm>LC</fnm></au><au><snm>Hagenn</snm><fnm>M</fnm></au><au><snm>Siqueira</snm><fnm>IR</fnm></au><au><snm>Araujo</snm><fnm>E</fnm></au><au><snm>Torres</snm><fnm>IL</fnm></au><au><snm>Gottfried</snm><fnm>C</fnm></au><au><snm>Netto</snm><fnm>CA</fnm></au><au><snm>Goncalves</snm><fnm>CA</fnm></au></aug><source>Neurochem Res</source><pubdate>2003</pubdate><volume>28</volume><fpage>1793</fpage><lpage>1797</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1023/A:1026107405399</pubid><pubid idtype="pmpid" link="fulltext">14649719</pubid></pubidlist></xrefbib></bibl><bibl id="B48"><title><p>Neuroprotective and diseasemodifying effects of the ketogenic diet</p></title><aug><au><snm>Gasior</snm><fnm>M</fnm></au><au><snm>Rogawski</snm><fnm>MA</fnm></au><au><snm>Hartman</snm><fnm>AL</fnm></au></aug><source>Behav Pharmacol</source><pubdate>2006</pubdate><volume>17</volume><fpage>431</fpage><lpage>439</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1097/00008877-200609000-00009</pubid><pubid idtype="pmcid">2367001</pubid><pubid idtype="pmpid">16940764</pubid></pubidlist></xrefbib></bibl><bibl id="B49"><title><p>Ketogenic diet, amino acid metabolism, and seizure control</p></title><aug><au><snm>Yudkoff</snm><fnm>M</fnm></au><au><snm>Daikhin</snm><fnm>Y</fnm></au><au><snm>Nissim</snm><fnm>I</fnm></au><au><snm>Lazarow</snm><fnm>A</fnm></au></aug><source>J Neurosci Res</source><pubdate>2001</pubdate><volume>66</volume><fpage>931</fpage><lpage>940</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/jnr.10083</pubid><pubid idtype="pmpid" link="fulltext">11746421</pubid></pubidlist></xrefbib></bibl><bibl id="B50"><title><p>Changes in cerebral blood flow and carbohydrate metabolism during acute hyperketonemia</p></title><aug><au><snm>Hasselbalch</snm><fnm>SG</fnm></au><au><snm>Madsen</snm><fnm>PL</fnm></au><au><snm>Hageman</snm><fnm>LP</fnm></au><au><snm>Olsen</snm><fnm>KS</fnm></au><au><snm>Justesen</snm><fnm>N</fnm></au><au><snm>Holm</snm><fnm>S</fnm></au><au><snm>Paulson</snm><fnm>OB</fnm></au></aug><source>Am J Physiol</source><pubdate>1996</pubdate><volume>270</volume><fpage>E746</fpage><lpage>E751</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">8967461</pubid></xrefbib></bibl><bibl id="B51"><title><p>Induction of monocarboxylate transporter 2 expression and ketone transport following traumatic brain injury in juvenile and adult rats</p></title><aug><au><snm>Prins</snm><fnm>ML</fnm></au><au><snm>Giza</snm><fnm>CC</fnm></au></aug><source>Dev Neurosci</source><pubdate>2006</pubdate><volume>28</volume><fpage>447</fpage><lpage>456</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1159/000094170</pubid><pubid idtype="pmpid" link="fulltext">16943667</pubid></pubidlist></xrefbib></bibl><bibl id="B52"><title><p>D-&#946;-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease</p></title><aug><au><snm>Tieu</snm><fnm>K</fnm></au><au><snm>Perier</snm><fnm>C</fnm></au><au><snm>Caspersen</snm><fnm>C</fnm></au><au><snm>Teismann</snm><fnm>P</fnm></au><au><snm>Wu</snm><fnm>DC</fnm></au><au><snm>Yan</snm><fnm>SD</fnm></au><au><snm>Naini</snm><fnm>A</fnm></au><au><snm>Vila</snm><fnm>M</fnm></au><au><snm>Jackson-Lewis</snm><fnm>V</fnm></au><au><snm>Ramasamy</snm><fnm>R</fnm></au><au><snm>Przedborski</snm><fnm>S</fnm></au></aug><source>J Clin Invest</source><pubdate>2003</pubdate><volume>112</volume><fpage>892</fpage><lpage>901</lpage><xrefbib><pubidlist><pubid idtype="pmcid">193668</pubid><pubid idtype="pmpid">12975474</pubid></pubidlist></xrefbib></bibl><bibl id="B53"><title><p>Persistent hyperglycemia in severe traumatic brain injury: an independent predictor of outcome</p></title><aug><au><snm>Salim</snm><fnm>A</fnm></au><au><snm>Hadjizacharia</snm><fnm>P</fnm></au><au><snm>Dubose</snm><fnm>J</fnm></au><au><snm>Brown</snm><fnm>C</fnm></au><au><snm>Inaba</snm><fnm>K</fnm></au><au><snm>Chan</snm><fnm>LS</fnm></au><au><snm>Margulies</snm><fnm>D</fnm></au></aug><source>Am Surg</source><pubdate>2009</pubdate><volume>75</volume><fpage>25</fpage><lpage>29</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">19213392</pubid></xrefbib></bibl><bibl id="B54"><title><p>Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation</p></title><aug><au><snm>Maalouf</snm><fnm>M</fnm></au><au><snm>Sullivan</snm><fnm>PG</fnm></au><au><snm>Davis</snm><fnm>L</fnm></au><au><snm>Kim</snm><fnm>DY</fnm></au><au><snm>Rho</snm><fnm>JM</fnm></au></aug><source>Neuroscience</source><pubdate>2007</pubdate><volume>145</volume><fpage>256</fpage><lpage>264</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/j.neuroscience.2006.11.065</pubid><pubid idtype="pmcid">1865572</pubid><pubid idtype="pmpid">17240074</pubid></pubidlist></xrefbib></bibl><bibl id="B55"><title><p>Acetoacetate protects hippocampal neurons against glutamate-mediated neuronal damage during glycolysis inhibition</p></title><aug><au><snm>Massieu</snm><fnm>L</fnm></au><au><snm>Haces</snm><fnm>ML</fnm></au><au><snm>Montiel</snm><fnm>T</fnm></au><au><snm>Hernandez-Fonseca</snm><fnm>K</fnm></au></aug><source>Neuroscience</source><pubdate>2003</pubdate><volume>120</volume><fpage>365</fpage><lpage>378</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/S0306-4522(03)00266-5</pubid><pubid idtype="pmpid" link="fulltext">12890508</pubid></pubidlist></xrefbib></bibl><bibl id="B56"><title><p>D-&#946;-Hydroxybutyrate prevents glutamate-mediated lipoperoxidation and neuronal damage elicited during glycolysis inhibition in vivo</p></title><aug><au><snm>Mejia-Toiber</snm><fnm>J</fnm></au><au><snm>Montiel</snm><fnm>T</fnm></au><au><snm>Massieu</snm><fnm>L</fnm></au></aug><source>Neurochem Res</source><pubdate>2006</pubdate><volume>31</volume><fpage>1399</fpage><lpage>1408</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/s11064-006-9189-5</pubid><pubid idtype="pmpid" link="fulltext">17115265</pubid></pubidlist></xrefbib></bibl><bibl id="B57"><title><p>Ketogenic diet protects the hippocampus from kainic acid toxicity by inhibiting the dissociation of bad from 14-3-3</p></title><aug><au><snm>Noh</snm><fnm>HS</fnm></au><au><snm>Kim</snm><fnm>YS</fnm></au><au><snm>Kim</snm><fnm>YH</fnm></au><au><snm>Han</snm><fnm>JY</fnm></au><au><snm>Park</snm><fnm>CH</fnm></au><au><snm>Kang</snm><fnm>AK</fnm></au><au><snm>Shin</snm><fnm>HS</fnm></au><au><snm>Kang</snm><fnm>SS</fnm></au><au><snm>Cho</snm><fnm>GJ</fnm></au><au><snm>Choi</snm><fnm>WS</fnm></au></aug><source>J Neurosci Res</source><pubdate>2006</pubdate><volume>84</volume><fpage>1829</fpage><lpage>1836</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/jnr.21057</pubid><pubid idtype="pmpid" link="fulltext">17058267</pubid></pubidlist></xrefbib></bibl><bibl id="B58"><title><p>The protective effect of a ketogenic diet on kainic acid-induced hippocampal cell death in the male ICR mice</p></title><aug><au><snm>Noh</snm><fnm>HS</fnm></au><au><snm>Kim</snm><fnm>YS</fnm></au><au><snm>Lee</snm><fnm>HP</fnm></au><au><snm>Chung</snm><fnm>KM</fnm></au><au><snm>Kim</snm><fnm>DW</fnm></au><au><snm>Kang</snm><fnm>SS</fnm></au><au><snm>Cho</snm><fnm>GJ</fnm></au><au><snm>Choi</snm><fnm>WS</fnm></au></aug><source>Epilepsy Res</source><pubdate>2003</pubdate><volume>53</volume><fpage>119</fpage><lpage>128</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/S0920-1211(02)00262-0</pubid><pubid idtype="pmpid" link="fulltext">12576173</pubid></pubidlist></xrefbib></bibl><bibl id="B59"><title><p>D-&#946;-Hydroxybutyrate is neuroprotective against hypoxia in serum-free hippocampal primary cultures</p></title><aug><au><snm>Masuda</snm><fnm>R</fnm></au><au><snm>Monahan</snm><fnm>JW</fnm></au><au><snm>Kashiwaya</snm><fnm>Y</fnm></au></aug><source>J Neurosci Res</source><pubdate>2005</pubdate><volume>80</volume><fpage>501</fpage><lpage>509</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/jnr.20464</pubid><pubid idtype="pmpid" link="fulltext">15825191</pubid></pubidlist></xrefbib></bibl><bibl id="B60"><title><p>Adaptation to chronic hypoxia during diet-induced ketosis</p></title><aug><au><snm>Puchowicz</snm><fnm>MA</fnm></au><au><snm>Emancipator</snm><fnm>DS</fnm></au><au><snm>Xu</snm><fnm>K</fnm></au><au><snm>Magness</snm><fnm>DL</fnm></au><au><snm>Ndubuizu</snm><fnm>OI</fnm></au><au><snm>Lust</snm><fnm>WD</fnm></au><au><snm>LaManna</snm><fnm>JC</fnm></au></aug><source>Adv Exp Med Biol</source><pubdate>2005</pubdate><volume>566</volume><fpage>51</fpage><lpage>57</lpage><xrefbib><pubidlist><pubid idtype="doi">full_text</pubid><pubid idtype="pmpid" link="fulltext">16594134</pubid></pubidlist></xrefbib></bibl><bibl id="B61"><title><p>Ketogenic diet reduces cytochrome c release and cellular apoptosis following traumatic brain injury in juvenile rats</p></title><aug><au><snm>Hu</snm><fnm>ZG</fnm></au><au><snm>Wang</snm><fnm>HD</fnm></au><au><snm>Jin</snm><fnm>W</fnm></au><au><snm>Yin</snm><fnm>HX</fnm></au></aug><source>Ann Clin Lab Sci</source><pubdate>2009</pubdate><volume>39</volume><fpage>76</fpage><lpage>83</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">19201746</pubid></xrefbib></bibl><bibl id="B62"><title><p>The protective effect of the ketogenic diet on traumatic brain injury-induced cell death in juvenile rats</p></title><aug><au><snm>Hu</snm><fnm>ZG</fnm></au><au><snm>Wang</snm><fnm>HD</fnm></au><au><snm>Qiao</snm><fnm>L</fnm></au><au><snm>Yan</snm><fnm>W</fnm></au><au><snm>Tan</snm><fnm>QF</fnm></au><au><snm>Yin</snm><fnm>HX</fnm></au></aug><source>Brain Injury</source><pubdate>2009</pubdate><volume>23</volume><fpage>459</fpage><lpage>465</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1080/02699050902788469</pubid><pubid idtype="pmpid" link="fulltext">19408168</pubid></pubidlist></xrefbib></bibl><bibl id="B63"><title><p>Beta-hydroxybutyrate, a cerebral function improving agent, protects rat brain against ischemic damage caused by permanent and transient focal cerebral ischemia</p></title><aug><au><snm>Suzuki</snm><fnm>M</fnm></au><au><snm>Suzuki</snm><fnm>M</fnm></au><au><snm>Kitamura</snm><fnm>Y</fnm></au><au><snm>Mori</snm><fnm>S</fnm></au><au><snm>Sato</snm><fnm>K</fnm></au><au><snm>Dohi</snm><fnm>S</fnm></au><au><snm>Sato</snm><fnm>T</fnm></au><au><snm>Matsuura</snm><fnm>A</fnm></au><au><snm>Hiraide</snm><fnm>A</fnm></au></aug><source>Jpn J Pharmacol</source><pubdate>2002</pubdate><volume>89</volume><fpage>36</fpage><lpage>43</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1254/jjp.89.36</pubid><pubid idtype="pmpid" link="fulltext">12083741</pubid></pubidlist></xrefbib></bibl><bibl id="B64"><title><p>Age-dependent reduction of cortical contusion volume by ketones after traumatic brain injury</p></title><aug><au><snm>Prins</snm><fnm>ML</fnm></au><au><snm>Fujima</snm><fnm>LS</fnm></au><au><snm>Hovda</snm><fnm>DA</fnm></au></aug><source>J Neurosci Res</source><pubdate>2005</pubdate><volume>82</volume><fpage>413</fpage><lpage>420</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/jnr.20633</pubid><pubid idtype="pmpid" link="fulltext">16180224</pubid></pubidlist></xrefbib></bibl><bibl id="B65"><title><p>Increased cerebral uptake and oxidation of exogenous betaHB improves ATP following traumatic brain injury in adult rats</p></title><aug><au><snm>Prins</snm><fnm>ML</fnm></au><au><snm>Lee</snm><fnm>SM</fnm></au><au><snm>Fujima</snm><fnm>LS</fnm></au><au><snm>Hovda</snm><fnm>DA</fnm></au></aug><source>J Neurochem</source><pubdate>2004</pubdate><volume>90</volume><fpage>666</fpage><lpage>672</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1111/j.1471-4159.2004.02542.x</pubid><pubid idtype="pmpid" link="fulltext">15255945</pubid></pubidlist></xrefbib></bibl><bibl id="B66"><title><p>Brain hydroxyl radical generation in acute experimental head injury</p></title><aug><au><snm>Hall</snm><fnm>ED</fnm></au><au><snm>Andrus</snm><fnm>PK</fnm></au><au><snm>Yonkers</snm><fnm>PA</fnm></au></aug><source>J Neurochem</source><pubdate>1993</pubdate><volume>60</volume><fpage>588</fpage><lpage>594</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1111/j.1471-4159.1993.tb03189.x</pubid><pubid idtype="pmpid">8380437</pubid></pubidlist></xrefbib></bibl><bibl id="B67"><title><p>Eff ects of chemical pretreatment on posttraumatic cortical edema in the rat</p></title><aug><au><snm>Biros</snm><fnm>MH</fnm></au><au><snm>Nordness</snm><fnm>R</fnm></au></aug><source>Am J Emerg Med</source><pubdate>1996</pubdate><volume>14</volume><fpage>27</fpage><lpage>32</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/S0735-6757(96)90008-X</pubid><pubid idtype="pmpid" link="fulltext">8630150</pubid></pubidlist></xrefbib></bibl><bibl id="B68"><title><p>Protective effect of fasting upon cerebralhypoxic-ischemic injury</p></title><aug><au><snm>Go</snm><fnm>KG</fnm></au><au><snm>Prenen</snm><fnm>GH</fnm></au><au><snm>Korf</snm><fnm>J</fnm></au></aug><source>Metab Brain Dis</source><pubdate>1988</pubdate><volume>3</volume><fpage>257</fpage><lpage>263</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/BF00999535</pubid><pubid idtype="pmpid">3241603</pubid></pubidlist></xrefbib></bibl><bibl id="B69"><title><p>Fasting prior to transient cerebral ischemia reduces delayed neuronal necrosis</p></title><aug><au><snm>Marie</snm><fnm>C</fnm></au><au><snm>Bralet</snm><fnm>AM</fnm></au><au><snm>Gueldry</snm><fnm>S</fnm></au><au><snm>Bralet</snm><fnm>J</fnm></au></aug><source>Metab Brain Dis</source><pubdate>1990</pubdate><volume>5</volume><fpage>65</fpage><lpage>75</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/BF01001047</pubid><pubid idtype="pmpid">2385215</pubid></pubidlist></xrefbib></bibl><bibl id="B70"><title><p>Effect of beta-hydroxybutyrate, a cerebral function improving agent, on cerebral hypoxia, anoxia and ischemia in mice and rats</p></title><aug><au><snm>Suzuki</snm><fnm>M</fnm></au><au><snm>Suzuki</snm><fnm>M</fnm></au><au><snm>Sato</snm><fnm>K</fnm></au><au><snm>Dohi</snm><fnm>S</fnm></au><au><snm>Sato</snm><fnm>T</fnm></au><au><snm>Matsuura</snm><fnm>A</fnm></au><au><snm>Hiraide</snm><fnm>A</fnm></au></aug><source>Jpn J Pharmacol</source><pubdate>2001</pubdate><volume>87</volume><fpage>143</fpage><lpage>150</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1254/jjp.87.143</pubid><pubid idtype="pmpid" link="fulltext">11700013</pubid></pubidlist></xrefbib></bibl><bibl id="B71"><title><p>D-&#946;- Hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease</p></title><aug><au><snm>Imamura</snm><fnm>K</fnm></au><au><snm>Takeshima</snm><fnm>T</fnm></au><au><snm>Kashiwaya</snm><fnm>Y</fnm></au><au><snm>Nakaso</snm><fnm>K</fnm></au><au><snm>Nakashima</snm><fnm>K</fnm></au></aug><source>J Neurosci Res</source><pubdate>2006</pubdate><volume>84</volume><fpage>1376</fpage><lpage>1384</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/jnr.21021</pubid><pubid idtype="pmpid" link="fulltext">16917840</pubid></pubidlist></xrefbib></bibl><bibl id="B72"><title><p>D-&#946;- Hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease</p></title><aug><au><snm>Kashiwaya</snm><fnm>Y</fnm></au><au><snm>Takeshima</snm><fnm>T</fnm></au><au><snm>Mori</snm><fnm>N</fnm></au><au><snm>Nakashima</snm><fnm>K</fnm></au><au><snm>Clarke</snm><fnm>K</fnm></au><au><snm>Veech</snm><fnm>RL</fnm></au></aug><source>Proc Natl Acad Sci USA</source><pubdate>2000</pubdate><volume>97</volume><fpage>5440</fpage><lpage>5444</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1073/pnas.97.10.5440</pubid><pubid idtype="pmcid">25847</pubid><pubid idtype="pmpid">10805800</pubid></pubidlist></xrefbib></bibl><bibl id="B73"><title><p>Distinct mechanisms of neurodegeneration induced by chronic complex I inhibition in dopaminergic and non-dopaminergic cells</p></title><aug><au><snm>Kweon</snm><fnm>GR</fnm></au><au><snm>Marks</snm><fnm>JD</fnm></au><au><snm>Krencik</snm><fnm>R</fnm></au><au><snm>Leung</snm><fnm>EH</fnm></au><au><snm>Schumacker</snm><fnm>PT</fnm></au><au><snm>Hyland</snm><fnm>K</fnm></au><au><snm>Kang</snm><fnm>UJ</fnm></au></aug><source>J Biol Chem</source><pubdate>2004</pubdate><volume>279</volume><fpage>51783</fpage><lpage>51792</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1074/jbc.M407336200</pubid><pubid idtype="pmpid" link="fulltext">15469939</pubid></pubidlist></xrefbib></bibl><bibl id="B74"><title><p>A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease</p></title><aug><au><snm>Van der Auwera</snm><fnm>I</fnm></au><au><snm>Wera</snm><fnm>S</fnm></au><au><snm>Van Leuven</snm><fnm>F</fnm></au><au><snm>Henderson</snm><fnm>ST</fnm></au></aug><source>Nutr Metab (Lond)</source><pubdate>2005</pubdate><volume>2</volume><fpage>28</fpage><xrefbib><pubidlist><pubid idtype="doi">10.1186/1743-7075-2-28</pubid><pubid idtype="pmcid">1282589</pubid><pubid idtype="pmpid">16229744</pubid></pubidlist></xrefbib></bibl><bibl id="B75"><title><p>D, L-3-Hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase defi ciency (MADD)</p></title><aug><au><snm>Van Hove</snm><fnm>JL</fnm></au><au><snm>Grunewald</snm><fnm>S</fnm></au><au><snm>Jaeken</snm><fnm>J</fnm></au><au><snm>Demaerel</snm><fnm>P</fnm></au><au><snm>Declercq</snm><fnm>PE</fnm></au><au><snm>Bourdoux</snm><fnm>P</fnm></au><au><snm>Niezen-Koning</snm><fnm>K</fnm></au><au><snm>Deanfeld</snm><fnm>JE</fnm></au><au><snm>Leonard</snm><fnm>JV</fnm></au></aug><source>Lancet</source><pubdate>2003</pubdate><volume>361</volume><fpage>1433</fpage><lpage>1435</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/S0140-6736(03)13105-4</pubid><pubid idtype="pmpid" link="fulltext">12727399</pubid></pubidlist></xrefbib></bibl><bibl id="B76"><title><p>The ketogenic diet: seizure control correlates better with serum beta-hydroxybutyrate than with urine ketones</p></title><aug><au><snm>Gilbert</snm><fnm>DL</fnm></au><au><snm>Pyzik</snm><fnm>PL</fnm></au><au><snm>Freeman</snm><fnm>JM</fnm></au></aug><source>J Child Neurol</source><pubdate>2000</pubdate><volume>15</volume><fpage>787</fpage><lpage>790</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1177/088307380001501203</pubid><pubid idtype="pmpid" link="fulltext">11198492</pubid></pubidlist></xrefbib></bibl><bibl id="B77"><title><p>KTX 0101: a potential metabolic approach to cytoprotection in major surgery and neurological disorders</p></title><aug><au><snm>Smith</snm><fnm>SL</fnm></au><au><snm>Heal</snm><fnm>DJ</fnm></au><au><snm>Martin</snm><fnm>KF</fnm></au></aug><source>CNS Drug Rev</source><pubdate>2005</pubdate><volume>11</volume><fpage>113</fpage><lpage>140</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1111/j.1527-3458.2005.tb00265.x</pubid><pubid idtype="pmpid">16007235</pubid></pubidlist></xrefbib></bibl><bibl id="B78"><title><p>Evaluation of a carbohydrate-free diet for patients with severe head injury</p></title><aug><au><snm>Ritter</snm><fnm>AM</fnm></au><au><snm>Robertson</snm><fnm>CS</fnm></au><au><snm>Goodman</snm><fnm>JC</fnm></au><au><snm>Contant</snm><fnm>CF</fnm></au><au><snm>Grossman</snm><fnm>RG</fnm></au></aug><source>J Neurotrauma</source><pubdate>1996</pubdate><volume>13</volume><fpage>473</fpage><lpage>485</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1089/neu.1996.13.473</pubid><pubid idtype="pmpid">8880611</pubid></pubidlist></xrefbib></bibl><bibl id="B79"><title><p>Effect of acute hyperketonemia on the cerebral uptake of ketone bodies in nondiabetic subjects and IDDM patients</p></title><aug><au><snm>Blomqvist</snm><fnm>G</fnm></au><au><snm>Alvarsson</snm><fnm>M</fnm></au><au><snm>Grill</snm><fnm>V</fnm></au><au><snm>Von Heijne</snm><fnm>G</fnm></au><au><snm>Ingvar</snm><fnm>M</fnm></au><au><snm>Thorell</snm><fnm>JO</fnm></au><au><snm>Stone-Elander</snm><fnm>S</fnm></au><au><snm>Widen</snm><fnm>L</fnm></au><au><snm>Ekberg</snm><fnm>K</fnm></au></aug><source>Am J Physiol Endocrinol Metab</source><pubdate>2002</pubdate><volume>283</volume><fpage>E20</fpage><lpage>E28</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">12067838</pubid></xrefbib></bibl><bibl id="B80"><title><p>Beneficial effects of ketogenic diet in obese diabetic subjects</p></title><aug><au><snm>Dashti</snm><fnm>HM</fnm></au><au><snm>Mathew</snm><fnm>TC</fnm></au><au><snm>Khadada</snm><fnm>M</fnm></au><au><snm>Al-Mousawi</snm><fnm>M</fnm></au><au><snm>Talib</snm><fnm>H</fnm></au><au><snm>Asfar</snm><fnm>SK</fnm></au><au><snm>Behbahani</snm><fnm>AI</fnm></au><au><snm>Al-Zaid</snm><fnm>NS</fnm></au></aug><source>Mol Cell Biochem</source><pubdate>2007</pubdate><volume>302</volume><fpage>249</fpage><lpage>256</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/s11010-007-9448-z</pubid><pubid idtype="pmpid" link="fulltext">17447017</pubid></pubidlist></xrefbib></bibl><bibl id="B81"><title><p>Effect of 3-hydroxybutyrate on posttraumatic metabolism in man</p></title><aug><au><snm>Hiraide</snm><fnm>A</fnm></au><au><snm>Katayama</snm><fnm>M</fnm></au><au><snm>Sugimoto</snm><fnm>H</fnm></au><au><snm>Yoshioka</snm><fnm>T</fnm></au><au><snm>Sugimoto</snm><fnm>T</fnm></au></aug><source>Surgery</source><pubdate>1991</pubdate><volume>109</volume><fpage>176</fpage><lpage>181</lpage><xrefbib><pubid idtype="pmpid">1992551</pubid></xrefbib></bibl><bibl id="B82"><title><p>Failure of infused beta-hydroxybutyrate to decrease proteolysis in man</p></title><aug><au><snm>Miles</snm><fnm>JM</fnm></au><au><snm>Nissen</snm><fnm>SL</fnm></au><au><snm>Rizza</snm><fnm>RA</fnm></au><au><snm>Gerich</snm><fnm>JE</fnm></au><au><snm>Haymond</snm><fnm>MW</fnm></au></aug><source>Diabetes</source><pubdate>1983</pubdate><volume>32</volume><fpage>197</fpage><lpage>205</lpage><xrefbib><pubidlist><pubid idtype="doi">10.2337/diabetes.32.3.197</pubid><pubid idtype="pmpid">6298041</pubid></pubidlist></xrefbib></bibl><bibl id="B83"><title><p>Rapid intravenous sodium acetoacetate infusion in man. Metabolic and kinetic responses</p></title><aug><au><snm>Owen</snm><fnm>OE</fnm></au><au><snm>Reichard</snm><fnm>GA</fnm></au><au><snm>Markus</snm><fnm>H</fnm></au><au><snm>Boden</snm><fnm>G</fnm></au><au><snm>Mozzoli</snm><fnm>MA</fnm></au><au><snm>Shuman</snm><fnm>CR</fnm></au></aug><source>J Clin Invest</source><pubdate>1973</pubdate><volume>52</volume><fpage>2606</fpage><lpage>2616</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1172/JCI107453</pubid><pubid idtype="pmcid">302521</pubid><pubid idtype="pmpid">4729054</pubid></pubidlist></xrefbib></bibl><bibl id="B84"><title><p>Effects of beta-hydroxybutyrate on cognition in memory-impaired adults</p></title><aug><au><snm>Reger</snm><fnm>MA</fnm></au><au><snm>Henderson</snm><fnm>ST</fnm></au><au><snm>Hale</snm><fnm>C</fnm></au><au><snm>Cholerton</snm><fnm>B</fnm></au><au><snm>Baker</snm><fnm>LD</fnm></au><au><snm>Watson</snm><fnm>GS</fnm></au><au><snm>Hyde</snm><fnm>K</fnm></au><au><snm>Chapman</snm><fnm>D</fnm></au><au><snm>Craft</snm><fnm>S</fnm></au></aug><source>Neurobiol Aging</source><pubdate>2004</pubdate><volume>25</volume><fpage>311</fpage><lpage>314</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/S0197-4580(03)00087-3</pubid><pubid idtype="pmpid" link="fulltext">15123336</pubid></pubidlist></xrefbib></bibl><bibl id="B85"><title><p>Blood-brain barrier permeability of glucose and ketone bodies during short-term starvation in humans</p></title><aug><au><snm>Hasselbalch</snm><fnm>SG</fnm></au><au><snm>Knudsen</snm><fnm>GM</fnm></au><au><snm>Jakobsen</snm><fnm>J</fnm></au><au><snm>Hageman</snm><fnm>LP</fnm></au><au><snm>Holm</snm><fnm>S</fnm></au><au><snm>Paulson</snm><fnm>OB</fnm></au></aug><source>Am J Physiol</source><pubdate>1995</pubdate><volume>268</volume><fpage>E1161</fpage><lpage>E1166</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">7611392</pubid></xrefbib></bibl><bibl id="B86"><title><p>The efficacy of the ketogenic diet - 1998: a prospective evaluation of intervention in 150 children</p></title><aug><au><snm>Freeman</snm><fnm>JM</fnm></au><au><snm>Vining</snm><fnm>EP</fnm></au><au><snm>Pillas</snm><fnm>DJ</fnm></au><au><snm>Pyzik</snm><fnm>PL</fnm></au><au><snm>Casey</snm><fnm>JC</fnm></au><au><snm>Kelly</snm><fnm>LM</fnm></au></aug><source>Pediatrics</source><pubdate>1998</pubdate><volume>102</volume><fpage>1358</fpage><lpage>1363</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1542/peds.102.6.1358</pubid><pubid idtype="pmpid" link="fulltext">9832569</pubid></pubidlist></xrefbib></bibl><bibl id="B87"><title><p>Nephrolithiasis associated with the ketogenic diet</p></title><aug><au><snm>Kielb</snm><fnm>S</fnm></au><au><snm>Koo</snm><fnm>HP</fnm></au><au><snm>Bloom</snm><fnm>DA</fnm></au><au><snm>Faerber</snm><fnm>GJ</fnm></au></aug><source>J Urol</source><pubdate>2000</pubdate><volume>164</volume><fpage>464</fpage><lpage>466</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/S0022-5347(05)67400-9</pubid><pubid idtype="pmpid" link="fulltext">10893623</pubid></pubidlist></xrefbib></bibl><bibl id="B88"><title><p>The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care. Initial management</p></title><source>J Neurotrauma</source><pubdate>2000</pubdate><volume>17</volume><fpage>463</fpage><lpage>469</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1089/neu.2000.17.463</pubid><pubid idtype="pmpid">10937888</pubid></pubidlist></xrefbib></bibl><bibl id="B89"><title><p>Cerebral edema: hypertonic saline solutions</p></title><aug><au><snm>Bhardwaj</snm><fnm>A</fnm></au><au><snm>Ulatowski</snm><fnm>JA</fnm></au></aug><source>Curr Treat Options Neurol</source><pubdate>1999</pubdate><volume>1</volume><fpage>179</fpage><lpage>188</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/s11940-999-0002-z</pubid><pubid idtype="pmpid">11096708</pubid></pubidlist></xrefbib></bibl><bibl id="B90"><title><p>Cerebral resuscitation: role of osmotherapy</p></title><aug><au><snm>Harukuni</snm><fnm>I</fnm></au><au><snm>Kirsch</snm><fnm>JR</fnm></au><au><snm>Bhardwaj</snm><fnm>A</fnm></au></aug><source>J Anesth</source><pubdate>2002</pubdate><volume>16</volume><fpage>229</fpage><lpage>237</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/s005400200030</pubid><pubid idtype="pmpid" link="fulltext">14517646</pubid></pubidlist></xrefbib></bibl><bibl id="B91"><title><p>A review of the efficacy and safety of 7.5% NaCl/6% dextran 70 in experimental animals and in humans</p></title><aug><au><snm>Dubick</snm><fnm>MA</fnm></au><au><snm>Wade</snm><fnm>CE</fnm></au></aug><source>J Trauma</source><pubdate>1994</pubdate><volume>36</volume><fpage>323</fpage><lpage>330</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1097/00005373-199403000-00007</pubid><pubid idtype="pmpid">7511708</pubid></pubidlist></xrefbib></bibl><bibl id="B92"><title><p>The effect of treatment with albumin, hetastarch, or hypertonic saline on neurological status and brain edema in a rat model of closed head trauma combined with uncontrolled hemorrhage and concurrent resuscitation in rats</p></title><aug><au><snm>Eilig</snm><fnm>I</fnm></au><au><snm>Rachinsky</snm><fnm>M</fnm></au><au><snm>Artru</snm><fnm>AA</fnm></au><au><snm>Alonchin</snm><fnm>A</fnm></au><au><snm>Kapuler</snm><fnm>V</fnm></au><au><snm>Tarnapolski</snm><fnm>A</fnm></au><au><snm>Shapira</snm><fnm>Y</fnm></au></aug><source>Anesth Analg</source><pubdate>2001</pubdate><volume>92</volume><fpage>669</fpage><lpage>675</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1097/00000539-200103000-00023</pubid><pubid idtype="pmpid" link="fulltext">11226099</pubid></pubidlist></xrefbib></bibl><bibl id="B93"><title><p>Head injury and hemorrhagic shock: studies of the blood brain barrier and intracranial pressure after resuscitation with normal saline solution, 3% saline solution, and dextran-40</p></title><aug><au><snm>Gunnar</snm><fnm>W</fnm></au><au><snm>Jonasson</snm><fnm>O</fnm></au><au><snm>Merlotti</snm><fnm>G</fnm></au><au><snm>Stone</snm><fnm>J</fnm></au><au><snm>Barrett</snm><fnm>J</fnm></au></aug><source>Surgery</source><pubdate>1988</pubdate><volume>103</volume><fpage>398</fpage><lpage>407</lpage><xrefbib><pubid idtype="pmpid">2451302</pubid></xrefbib></bibl><bibl id="B94"><title><p>Effect of small-volume resuscitation on intracranial pressure and related cerebral variables</p></title><aug><au><snm>Shackford</snm><fnm>SR</fnm></au></aug><source>J Trauma</source><pubdate>1997</pubdate><volume>42</volume><fpage>S48</fpage><lpage>S53</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1097/00005373-199705001-00009</pubid><pubid idtype="pmpid" link="fulltext">9191696</pubid></pubidlist></xrefbib></bibl><bibl id="B95"><title><p>7.2% NaCl/10% dextran 60 versus 20% mannitol for treatment of intracranial hypertension</p></title><aug><au><snm>Berger</snm><fnm>S</fnm></au><au><snm>Schurer</snm><fnm>L</fnm></au><au><snm>Hartl</snm><fnm>R</fnm></au><au><snm>Deisbock</snm><fnm>T</fnm></au><au><snm>Dautermann</snm><fnm>C</fnm></au><au><snm>Murr</snm><fnm>R</fnm></au><au><snm>Messmer</snm><fnm>K</fnm></au><au><snm>Baethmann</snm><fnm>A</fnm></au></aug><source>Acta Neurochir Suppl (Wien)</source><pubdate>1994</pubdate><volume>60</volume><fpage>494</fpage><lpage>498</lpage><xrefbib><pubid idtype="pmpid">7526628</pubid></xrefbib></bibl><bibl id="B96"><title><p>Comparison between hypertonic saline and mannitol in the reduction of elevated intracranial pressure in a rodent model of acute cerebral injury</p></title><aug><au><snm>Mirski</snm><fnm>AM</fnm></au><au><snm>Denchev</snm><fnm>ID</fnm></au><au><snm>Schnitzer</snm><fnm>SM</fnm></au><au><snm>Hanley</snm><fnm>FD</fnm></au></aug><source>J Neurosurg Anesthesiol</source><pubdate>2000</pubdate><volume>12</volume><fpage>334</fpage><lpage>344</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1097/00008506-200010000-00006</pubid><pubid idtype="pmpid" link="fulltext">11147382</pubid></pubidlist></xrefbib></bibl><bibl id="B97"><title><p>Prehospital hypertonic saline resuscitation of patients with hypotension and severe traumatic brain injury: a randomized controlled trial</p></title><aug><au><snm>Cooper</snm><fnm>DJ</fnm></au><au><snm>Myles</snm><fnm>PS</fnm></au><au><snm>McDermott</snm><fnm>FT</fnm></au><au><snm>Murray</snm><fnm>LJ</fnm></au><au><snm>Laidlaw</snm><fnm>J</fnm></au><au><snm>Cooper</snm><fnm>G</fnm></au><au><snm>Tremayne</snm><fnm>AB</fnm></au><au><snm>Bernard</snm><fnm>SS</fnm></au><au><snm>Ponsford</snm><fnm>J</fnm></au></aug><source>JAMA</source><pubdate>2004</pubdate><volume>291</volume><fpage>1350</fpage><lpage>1357</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1001/jama.291.11.1350</pubid><pubid idtype="pmpid" link="fulltext">15026402</pubid></pubidlist></xrefbib></bibl><bibl id="B98"><title><p>A multicenter trial for resuscitation of injured patients with 7.5% sodium chloride. The effect of added dextran 70. The Multicenter Group for the Study of Hypertonic Saline in Trauma Patients</p></title><aug><au><snm>Vassar</snm><fnm>MJ</fnm></au><au><snm>Fischer</snm><fnm>RP</fnm></au><au><snm>O'Brien</snm><fnm>PE</fnm></au><au><snm>Bachulis</snm><fnm>BL</fnm></au><au><snm>Chambers</snm><fnm>JA</fnm></au><au><snm>Hoyt</snm><fnm>DB</fnm></au><au><snm>Holcroft</snm><fnm>JW</fnm></au></aug><source>Arch Surg</source><pubdate>1993</pubdate><volume>128</volume><fpage>1003</fpage><lpage>1011</lpage><note>discussion 1011-1013</note><xrefbib><pubid idtype="pmpid" link="fulltext">7690225</pubid></xrefbib></bibl><bibl id="B99"><title><p>Prehospital resuscitation of hypotensive trauma patients with 7.5% NaCl versus 7.5% NaCl with added dextran: a controlled trial</p></title><aug><au><snm>Vassar</snm><fnm>MJ</fnm></au><au><snm>Perry</snm><fnm>CA</fnm></au><au><snm>Holcroft</snm><fnm>JW</fnm></au></aug><source>J Trauma</source><pubdate>1993</pubdate><volume>34</volume><fpage>622</fpage><lpage>632</lpage><note>discussion 632-633</note><xrefbib><pubidlist><pubid idtype="doi">10.1097/00005373-199305000-00003</pubid><pubid idtype="pmpid">7684457</pubid></pubidlist></xrefbib></bibl><bibl id="B100"><title><p>Malignant cerebral edema in patients with hypertensive intracerebral hemorrhage associated with hypertonic saline infusion: a rebound phenomenon?</p></title><aug><au><snm>Qureshi</snm><fnm>AI</fnm></au><au><snm>Suarez</snm><fnm>JI</fnm></au><au><snm>Bhardwaj</snm><fnm>A</fnm></au></aug><source>J Neurosurg Anesthesiol</source><pubdate>1998</pubdate><volume>10</volume><fpage>188</fpage><lpage>192</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1097/00008506-199807000-00010</pubid><pubid idtype="pmpid" link="fulltext">9681408</pubid></pubidlist></xrefbib></bibl><bibl id="B101"><title><p>Use of hypertonic (3%) saline/acetate infusion in the treatment of cerebral edema: effect on intracranial pressure and lateral displacement of the brain</p></title><aug><au><snm>Qureshi</snm><fnm>AI</fnm></au><au><snm>Suarez</snm><fnm>JI</fnm></au><au><snm>Bhardwaj</snm><fnm>A</fnm></au><au><snm>Mirski</snm><fnm>M</fnm></au><au><snm>Schnitzer</snm><fnm>MS</fnm></au><au><snm>Hanley</snm><fnm>DF</fnm></au><au><snm>Ulatowski</snm><fnm>JA</fnm></au></aug><source>Crit Care Med</source><pubdate>1998</pubdate><volume>26</volume><fpage>440</fpage><lpage>446</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1097/00003246-199803000-00011</pubid><pubid idtype="pmpid" link="fulltext">9504569</pubid></pubidlist></xrefbib></bibl><bibl id="B102"><title><p>Neurocardiac toxicity of racemic D, L-lactate fluids</p></title><aug><au><snm>Chan</snm><fnm>L</fnm></au><au><snm>Slater</snm><fnm>J</fnm></au><au><snm>Hasbargen</snm><fnm>J</fnm></au><au><snm>Herndon</snm><fnm>DN</fnm></au><au><snm>Veech</snm><fnm>RL</fnm></au><au><snm>Wolf</snm><fnm>S</fnm></au></aug><source>Integr Physiol Behav Sci</source><pubdate>1994</pubdate><volume>29</volume><fpage>383</fpage><lpage>394</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/BF02691358</pubid><pubid idtype="pmpid">7696135</pubid></pubidlist></xrefbib></bibl></refgrp>
</bm></art>